Professor David J Brooks

Publications


Journals

  • Edison P; Hinz R; Ramlackhansingh A; Thomas J; Gelosa G; Archer HA; Turkheimer FE; Brooks DJ. (27 Jan 2012). Can target-to-pons ratio be used as a reliable method for the analysis of [(11)C]PIB brain scans?. Neuroimage. DOI.
  • Lewis SJ; Pavese N; Rivero-Bosch M; Eggert K; Oertel W; Mathias CJ; Brooks DJ; Gerhard A. (12 Jan 2012). Brain monoamine systems in multiple system atrophy: A positron emission tomography study. Neurobiol Dis. DOI.
  • Grover VP; Pavese N; Koh SB; Wylezinska M; Saxby BK; Gerhard A; Forton DM; Brooks DJ; et alThomas HC; Taylor-Robinson SD. (Feb 2012). Cerebral microglial activation in patients with hepatitis c: in vivo evidence of neuroinflammation. J Viral Hepat. 19:e89-e96. DOI.
  • Brooks DJ. (Jan 2012). Can imaging separate multiple system atrophy from Parkinson's disease?. Mov Disord. 27:3-5. DOI.
  • Brooks DJ. (Jan 2012). Parkinson's disease: diagnosis. Parkinsonism Relat Disord. 18 Suppl 1:S31-S33. DOI.
  • Pavese N; Simpson BS; Metta V; Ramlackhansingh A; Chaudhuri KR; Brooks DJ. (16 Jan 2012). [¹⁸F]FDOPA uptake in the raphe nuclei complex reflects serotonin transporter availability. A combined [¹⁸F]FDOPA and [¹¹C]DASB PET study in Parkinson's disease. Neuroimage. 59:1080-1084. DOI.
  • Ostrowitzki S; Deptula D; Thurfjell L; Barkhof F; Bohrmann B; Brooks DJ; Klunk WE; Ashford E; et alYoo K; Xu ZX; Loetscher H; Santarelli L. (10 Oct 2011). Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab. Arch Neurol. DOI.
  • Ramlackhansingh AF; Brooks DJ; Greenwood RJ; Bose SK; Turkheimer FE; Kinnunen KM; Gentleman S; Heckemann RA; et alGunanayagam K; Gelosa G; Sharp DJ. (Sep 2011). Inflammation after Trauma: Microglial Activation and Traumatic Brain Injury. ANN NEUROL. 70:374-383. DOI.
  • Brooks DJ; Pavese N. (Dec 2011). Imaging biomarkers in Parkinson's disease. Prog Neurobiol. 95:614-628. DOI.
  • Edison P; Hinz R; Brooks DJ. (2011). Technical aspects of amyloid imaging for Alzheimer's disease. Alzheimers Res Ther. 3:25. DOI.
  • Politis M; Loane C; Wu K; Brooks DJ; Piccini P. (Sep 2011). Serotonergic mediated body mass index changes in Parkinson's disease. Neurobiol Dis. 43:609-615. DOI.
  • Politis M; Loane C; Wu K; Brooks DJ; Piccini P. (Sep 2011). Serotonergic mediated body mass index changes in Parkinson's disease. NEUROBIOL DIS. 43:609-615. DOI.
  • Ramlackhansingh AF; Brooks DJ; Greenwood RJ; Bose SK; Turkheimer FE; Kinnunen KM; Gentleman S; Heckemann RA; et alGunanayagam K; Gelosa G; Sharp DJ. (Sep 2011). Inflammation after trauma: microglial activation and traumatic brain injury. Ann Neurol. 70:374-383. DOI.
  • Stoessl AJ; Brooks DJ; Eidelberg D. (May 2011). Milestones in Neuroimaging. MOVEMENT DISORD. 26:968-978. DOI.
  • Pavese N; Rivero-Bosch M; Lewis SJ; Whone AL; Brooks DJ. (1 Jun 2011). Progression of monoaminergic dysfunction in Parkinson's disease: A longitudinal F-18-dopa PET study. NEUROIMAGE. 56:1463-1468. DOI.
  • Ramlackhansingh AF; Bose SK; Ahmed I; Turkheimer FE; Pavese N; Brooks DJ. (24 May 2011). Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology. 76:1811-1816. DOI.
  • Politis M; Oertel WH; Wu K; Quinn NP; Pogarell O; Brooks DJ; Bjorklund A; Lindvall O; et alPiccini P. (Sep 2011). Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Mov Disord. 26:1997-2003. DOI.
  • Boecker H; Brooks DJ. (Feb 2011). Resting Tremor in Parkinson Disease: Is the Pallidum to Blame?. ANN NEUROL. 69:229-231. DOI.
  • Ahmed I; Bose SK; Pavese N; Ramlackhansingh A; Turkheimer F; Hotton G; Hammers A; Brooks DJ. (Apr 2011). Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. Brain. 134:979-986. DOI.
  • Sastre M; Richardson JC; Gentleman SM; Brooks DJ. (Mar 2011). Inflammatory risk factors and pathologies associated with Alzheimer's disease. Curr Alzheimer Res. 8:132-141.
  • Knight WD; Okello AA; Ryan NS; Turkheimer FE; Rodríguez Martinez de Llano S; Edison P; Douglas J; Fox NC; et alBrooks DJ; Rossor MN. (Jan 2011). Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain. 134:293-300. DOI.
  • Politis M; Pavese N; Tai YF; Kiferle L; Mason SL; Brooks DJ; Tabrizi SJ; Barker RA; et alPiccini P. (Feb 2011). Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp. 32:258-270. DOI.
  • Ramlackhansingh A; Bose SK; Ahmed I; Pavese N; Brooks DJ; Turkheimer FE. (Nov 2010). PATH51 Investigating adenosine A2A receptor availability in Parkinson's disease patients with and without levodopa induced dyskinesias with [11C]SCH442416 PET. J Neurol Neurosurg Psychiatry. 81:e21. DOI.
  • Tai YF; Hoshi R; Brignell CM; Cohen L; Brooks DJ; Curran HV; Piccini P. (Mar 2011). Persistent nigrostriatal dopaminergic abnormalities in ex-users of MDMA ('Ecstasy'): an 18F-dopa PET study. Neuropsychopharmacology. 36:735-743. DOI.
  • Politis M; Wu K; Loane C; Turkheimer FE; Molloy S; Brooks DJ; Piccini P. (23 Nov 2010). Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology. 75:1920-1927. DOI.
  • Brooks DJ; Leinonen M; Nissinen H. (15 Sep 2010). Comparison of Direct Switch to Levodopa/Carbidopa/Entacapone in Levodopa/Benserazide-treated and Levodopa/Carbidopa-Treated Patients: A Meta-Analysis. MOVEMENT DISORD. 25:S667-S667.
  • Brooks DJ; Pavese N. (2009). Recent imaging advances in the diagnosis and management of Parkinson's disease. F1000 Med Rep. 1. DOI.
  • Brooks DJ. (Oct 2010). Imaging dopamine transporters in Parkinson's disease. Biomark Med. 4:651-660. DOI.
  • Brooks DJ; Pavese N. (2010). Imaging non-motor aspects of Parkinson's disease. Prog Brain Res. 184:205-218. DOI.
  • Pavese N; Metta V; Bose SK; Chaudhuri KR; Brooks DJ. (Nov 2010). Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain. 133:3434-3443. DOI.
  • Lingford-Hughes A; Reid AG; Myers J; Feeney A; Hammers A; Taylor LG; Rosso L; Turkheimer F; et alBrooks DJ; Grasby P; Nutt DJ. (Feb 2012). A [11C]Ro15 4513 PET study suggests that alcohol dependence in man is associated with reduced α5 benzodiazepine receptors in limbic regions. J Psychopharmacol. 26:273-281. DOI.
  • Vandenberghe R; Van Laere K; Ivanoiu A; Salmon E; Bastin C; Triau E; Hasselbalch S; Law I; et alAndersen A; Korner A; Minthon L; Garraux G; Nelissen N; Bormans G; Buckley C; Owenius R; Thurfjell L; Farrar G; Brooks DJ. (Sep 2010). F-18-Flutemetamol Amyloid Imaging in Alzheimer Disease and Mild Cognitive Impairment A Phase 2 Trial. ANN NEUROL. 68:319-329. DOI.
  • Boecker H; Weindl A; Brooks DJ; Ceballos-Baumann AO; Liedtke C; Miederer M; Sprenger T; Wagner KJ; et alMiederer I. (1 Jul 2010). GABAergic Dysfunction in Essential Tremor: An C-11-Flumazenil PET Study. J NUCL MED. 51:1030-1035. DOI.
  • Politis M; Wu K; Loane C; Kiferle L; Molloy S; Brooks DJ; Piccini P. (Oct 2010). Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol Dis. 40:216-221. DOI.
  • Politis M; Wu K; Loane C; Quinn NP; Brooks DJ; Rehncrona S; Bjorklund A; Lindvall O; et alPiccini P. (30 Jun 2010). Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci Transl Med. 2:38ra46. DOI.
  • Rice CM; Mallam EA; Whone AL; Walsh P; Brooks DJ; Kane N; Butler SR; Marks DI; et alScolding NJ. (Jun 2010). Safety and Feasibility of Autologous Bone Marrow Cellular Therapy in Relapsing-Progressive Multiple Sclerosis. CLIN PHARMACOL THER. 87:679-685. DOI.
  • Rinne JO; Brooks DJ; Rossor MN; Fox NC; Bullock R; Klunk WE; Mathis CA; Blennow K; et alBarakos J; Okello AA; de Llano SRM; Liu E; Koller M; Gregg KM; Schenk D; Black R; Grundman M. (Apr 2010). C-11-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. LANCET NEUROL. 9:363-372. DOI.
  • Brooks DJ; Papapetropoulos S; Vandenhende F; Tomic D; He P; Coppell A; O'Neill G. (Mar 2010). An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers. Clin Neuropharmacol. 33:55-60. DOI.
  • Brooks DJ. (Apr 2010). Imaging approaches to Parkinson disease. J Nucl Med. 51:596-609. DOI.
  • Rodda J; Okello A; Edison P; Dannhauser T; Brooks DJ; Walker Z. (11)C-PIB PET in subjective cognitive impairment. Eur Psychiatry.
  • Brooks DJ. (2010). Examining Braak's hypothesis by imaging Parkinson's disease. Mov Disord. 25 Suppl 1:S83-S88. DOI.
  • Dodel R; Spottke A; Gerhard A; Reuss A; Reinecker S; Schimke N; Trenkwalder C; Sixel-Döring F; et alHerting B; Kamm C; Gasser T; Sawires M; Geser F; Köllensperger M; Seppi K; Kloss M; Krause M; Daniels C; Deuschl G; Böttger S; Naumann M; Lipp A; Gruber D; Kupsch A; Du Y; Turkheimer F; Brooks DJ; Klockgether T; Poewe W; Wenning G; Schade-Brittinger C; Oertel WH; Eggert K. (15 Jan 2010). Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord. 25:97-107. DOI.
  • Pavese N; Moore RY; Scherfler C; Khan NL; Hotton G; Quinn NP; Bhatia KP; Wood NW; et alBrooks DJ; Lees AJ; Piccini P. (Mar 2010). In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study. Exp Neurol. 222:120-124. DOI.
  • Koole M; Lewis DM; Buckley C; Nelissen N; Vandenbulcke M; Brooks DJ; Vandenberghe R; Van Laere K. (1 May 2009). Whole-Body Biodistribution and Radiation Dosimetry of F-18-GE067: A Radioligand for In Vivo Brain Amyloid Imaging. J NUCL MED. 50:818-822. DOI.
  • Pavese N; Khan NL; Scherfler C; Cohen L; Brooks DJ; Wood NW; Bhatia KP; Quinn NP; et alLees AJ; Piccini P. (15 Nov 2009). Nigrostriatal Dysfunction in Homozygous and Heterozygous Parkin Gene Carriers: An F-18-Dopa PET Progression Study. MOVEMENT DISORD. 24:2260-2266. DOI.
  • Brooks DJ. (2009). Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography. Mov Disord. 24 Suppl 2:S742-S747. DOI.
  • Pavese N; Politis M; Tai YF; Barker RA; Tabrizi SJ; Mason SL; Brooks DJ; Piccini P. (Feb 2010). Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. Neurobiol Dis. 37:356-361. DOI.
  • Hu MT; Taylor-Robinson SD; Bell JD; Clough C; Brooks DJ; Chaudhuri KR; Turjanski N. (Apr 1998). Evidence for subclinical cortical dysfunction in Parkinson's disease patients: A proton magnetic resonance spectroscopy (H-1 MRS) study. NEUROLOGY. 50:A388-A388.
  • Taylor-Robinson SD; Weeks RA; Sargentoni J; Marcus CD; Bryant DJ; Harding AE; Brooks DJ. (7 May 1994). Evidence for glutamate excitotoxicity in Huntington's disease with proton magnetic resonance spectroscopy. Lancet. 343:1170.
  • Nelissen N; Van Laere K; Thurfjell L; Owenius R; Vandenbulcke M; Koole M; Bormans G; Brooks DJ; et alVandenberghe R. (Aug 2009). Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med. 50:1251-1259. DOI.
  • Edison P; Brooks DJ; Turkheimer FE; Archer HA; Hinz R. (1 Nov 2009). Strategies for the generation of parametric images of [11C]PIB with plasma input functions considering discriminations and reproducibility. Neuroimage. 48:329-338. DOI.
  • Williams TM; Davies SJ; Taylor LG; Daglish MR; Hammers A; Brooks DJ; Nutt DJ; Lingford-Hughes A. (Oct 2009). Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: an [11C]diprenorphine PET study. Eur Neuropsychopharmacol. 19:740-748. DOI.
  • Okello A; Koivunen J; Edison P; Archer HA; Turkheimer FE; Någren K; Bullock R; Walker Z; et alKennedy A; Fox NC; Rossor MN; Rinne JO; Brooks DJ. (8 Sep 2009). Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology. 73:754-760. DOI.
  • Brooks DJ; Seppi K; Neuroimaging Working Grp MSA. (15 May 2009). Proposed Neuroimaging Criteria for the Diagnosis of Multiple System Atrophy. MOVEMENT DISORD. 24:949-964. DOI.
  • Giladi N; Tal J; Azulay T; Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe WH; et alStocchi F; Tolosa E. (15 Apr 2009). Validation of the Freezing of Gait Questionnaire in Patients with Parkinson's Disease. MOVEMENT DISORD. 24:655-661. DOI.
  • Okello A; Edison P; Archer HA; Turkheimer FE; Kennedy J; Bullock R; Walker Z; Kennedy A; et alFox N; Rossor M; Brooks DJ. (6 Jan 2009). Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology. 72:56-62. DOI.
  • Edison P; Rowe CC; Rinne JO; Ng S; Ahmed I; Kemppainen N; Villemagne VL; O'Keefe G; et alNagren K; Chaudhury KR; Masters CL; Brooks DJ. (Dec 2008). Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J NEUROL NEUROSUR PS. 79:1331-1338. DOI.
  • Brooks DJ. (Sep 2008). The Role of Structural and Functional Imaging in Parkinsonian States with a Description of PET Technology. SEMIN NEUROL. 28:435-445. DOI.
  • Brooks DJ. (2007). Assessment of Parkinson's disease with imaging. Parkinsonism Relat Disord. 13 Suppl 3:S268-S275. DOI.
  • Pavese N; Brooks DJ. (Jul 2009). Imaging neurodegeneration in Parkinson's disease. Biochim Biophys Acta. 1792:722-729. DOI.
  • Gilman S; Wenning GK; Low PA; Brooks DJ; Mathias CJ; Trojanowski JQ; Wood NW; Colosimo C; et alDuerr A; Fowler CJ; Kaufmann H; Klockgether T; Lees A; Poewe W; Quinn N; Revesz T; Robertson D; Sandroni P; Seppi K; Vidailhet M. (26 Aug 2008). Second consensus statement on the diagnosis of multiple system atrophy. NEUROLOGY. 71:670-676.
  • Edison P; Archer HA; Gerhard A; Hinz R; Pavese N; Turkheimer FE; Hammers A; Tai YF; et alFox N; Kennedy A; Rossor M; Brooks DJ. (Dec 2008). Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis. 32:412-419. DOI.
  • Politis M; Piccini P; Pavese N; Koh SB; Brooks DJ. (Nov 2008). Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study. Exp Neurol. 214:112-116. DOI.
  • Brooks DJ. (Feb 2008). Optimizing levodopa therapy for Parkinson's disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. Neuropsychiatr Dis Treat. 4:39-47.
  • Reuter I; Tai YF; Pavese N; Chaudhuri KR; Mason S; Polkey CE; Clough C; Brooks DJ; et alBarker RA; Piccini P. (Aug 2008). Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease. J NEUROL NEUROSUR PS. 79:948-951. DOI.
  • Tomasi G; Edison P; Bertoldo A; Roncaroli F; Singh P; Gerhard A; Cobelli C; Brooks DJ; et alTurkheimer FE. (Aug 2008). Novel reference region model reveals increased microglial and reduced vascular binding of 11C-(R)-PK11195 in patients with Alzheimer's disease. J Nucl Med. 49:1249-1256. DOI.
  • Daglish MRC; Williams TM; Wilson SJ; Taylor LG; Eap CB; Augsburger M; Giroud C; Brooks DJ; et alMyles JS; Grasby P; Lingford-Hughes AR; Nutt DJ. (Jul 2008). Brain dopamine response in human opioid addiction. BRIT J PSYCHIAT. 193:65-72. DOI.
  • Brooks DJ; Doder M; Osman S; Luthra SK; Hirani E; Hume S; Kase H; Kilborn J; et alMartindill S; Mori A. (Sep 2008). Positron emission tomography analysis of [11C]KW-6002 binding to human and rat adenosine A2A receptors in the brain. Synapse. 62:671-681. DOI.
  • Stocchi F; Brooks DJ; Melamed E; Oertel W; Poewe W; Rascol O; Tolosa E. (Sep 2004). Effect of rasagiline on severity of OFF in Parkinson's disease. EUR J NEUROL. 11:253-254.
  • Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E. (Sep 2004). Effect of rasagiline on tremor in levodopa-treated Parkinson's disease patients (LARGO Study). EUR J NEUROL. 11:253-253.
  • Giladi N; Brooks DJ; Melamed E; Oertel W; Poewe W; Rascol O; Stocchi F; Tolosa E. (Sep 2004). Rasagiline treatment can improve freezing of gait in advanced Parkinson's disease; a prospective randomized, double-blind, placebo- and entacapone-controlled study. EUR J NEUROL. 11:247-247.
  • Brooks DJ; Korczyn AD; Rascol O. (Sep 2005). The therapeutic reserve: Ropinirole in Parkinson's disease (PD). EUR J NEUROL. 12:95-96.
  • Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E. (Sep 2005). Rasagiline is effective and well tolerated in the treatment of moderate to advanced Parkinson's disease patients receiving concomitant dopamine agonist therapy. EUR J NEUROL. 12:15-15.
  • Sawamoto N; Piccini P; Hotton G; Pavese N; Thielemans K; Brooks DJ. (May 2008). Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. BRAIN. 131:1294-1302. DOI.
  • Klinge PA; Brooks DJ; Samii A; Weckesser E; van den Hoff J; Fricke H; Brinker T; Knapp WH; et alBerding G. (Apr 2008). Correlates of local cerebral blood flow (CBF) in normal pressure hydrocephalus patients before and after shunting - A retrospective analysis of [O-15]H2O PET-CBF studies in 65 patients. CLIN NEUROL NEUROSUR. 110:369-375. DOI.
  • Brooks DJ. (May 2008). Technology insight: imaging neurodegeneration in Parkinson's disease. Nat Clin Pract Neurol. 4:267-277. DOI.
  • Wicks P; Turner MR; Abrahams S; Hammers A; Brooks DJ; Leigh PN; Goldstein LH. (2008). Neuronal loss associated with cognitive performance in amyotrophic lateral sclerosis: An (C-11)-flumazenil PET study. AMYOTROPH LATERAL SC. 9:43-49. DOI.
  • Brooks DJ; Leinonen M; Kuoppamäki M; Nissinen H. (Jun 2008). Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease. J Neural Transm. 115:843-849. DOI.
  • Moore RY; Whone AL; Brooks DJ. (Mar 2008). Extrastriatal monoamine neuron function in Parkinson's disease: an 18F-dopa PET study. Neurobiol Dis. 29:381-390. DOI.
  • Turner MR; Hammers A; Allsop J; Al-Chalabi A; Shaw CE; Brooks DJ; Leigh PN; Andersen PM. (2007). Volumetric cortical loss in sporadic and familial amyotrophic lateral sclerosis. AMYOTROPH LATERAL SC. 8:343-347. DOI.
  • Ahsan RL; Allom R; Gousias IS; Habib H; Turkheimer FE; Free S; Lemieux L; Myers R; et alDuncan JS; Brooks DJ; Koepp MJ; Hammers A. (1 Nov 2007). Volumes, spatial extents and a probabilistic atlas of the human basal ganglia and thalamus. NEUROIMAGE. 38:261-270. DOI.
  • Hammers A; Asselin MC; Turkheimer FE; Hinz R; Osman S; Hotton G; Brooks DJ; Duncan JS; et alKoepp MJ. (15 Oct 2007). Balancing bias, reliability, noise properties and the need for parametric maps in quantitative ligand PET: [C-11]diprenorphine test-retest data. NEUROIMAGE. 38:82-94. DOI.
  • Turner MR; Hammers A; Al-Chalabi A; Shaw CE; Andersen PM; Brooks DJ; Leigh PN. (Aug 2007). Cortical involvement in four cases of primary lateral sclerosis using [C-11]-flumazenil PET. J NEUROL. 254:1033-1036. DOI.
  • Williams TM; Daglish MRC; Lingford-Hughes A; Taylor LG; Hammers A; Brooks DJ; Grasby P; Myles JS; et alNutt DJ. (Jul 2007). Brain opioid receptor binding in early abstinence from opioid dependence - Positron emission tomography study. BRIT J PSYCHIAT. 191:63-69. DOI.
  • Minguez-Castellanos A; Escamilla-Sevilla F; Hotton GR; Toledo-Aral JJ; Ortega-Moreno A; Mendez-Ferrer S; Martin-Linares JM; Katati MJ; et alMir P; Villadiego J; Meersmans M; Perez-Garcia M; Brooks DJ; Arjona V; Lopez-Barneo J. (Aug 2007). Carotid body autotransplantation in Parkinson disease: a clinical and positron emission tomography study. J NEUROL NEUROSUR PS. 78:825-831. DOI.
  • Tai YF; Pavese N; Gerhard A; Tabrizi SJ; Barker RA; Brooks DJ; Piccini P. (Jul 2007). Microglial activation in presymptomatic Huntington's disease gene carriers. BRAIN. 130:1759-1766. DOI.
  • Brooks DJ. (Feb 1997). Motor disturbance and brain functional imaging in Parkinson's disease. EUR NEUROL. 38:26-32.
  • Thobois S; Hotton GR; Pinto S; Wilkinson L; Limousin-Dowsey P; Brooks DJ; Jahanshahi M. (Jun 2007). STN stimulation alters pallidal-frontal coupling during response selection under competition. J CEREBR BLOOD F MET. 27:1173-1184. DOI.
  • Hammers A; Panagoda P; Heckemann RA; Kelsch W; Turkheimer FE; Brooks DJ; Duncan JS; Koepp MJ. (Jan 2008). [11C]Flumazenil PET in temporal lobe epilepsy: do we need an arterial input function or kinetic modeling?. J Cereb Blood Flow Metab. 28:207-216. DOI.
  • Turner MR; Rabiner EA; Al-Chalabi A; Shaw CE; Brooks DJ; Leigh PN; Andersen PM. (10 Apr 2007). Cortical 5-HT1A receptor binding in patients with homozygous D90A SOD1 vs sporadic ALS. NEUROLOGY. 68:1233-1235.
  • Brooks DJ. (Oct 2006). Imaging the role of dopamine in health and disease Parkinson's disease as a lesion model. Wien Klin Wochenschr. 118:570-572. DOI.
  • Anderson AN; Pavese N; Edison P; Tai YF; Hammers A; Gerhard A; Brooks DJ; Turkheimer FE. (15 May 2007). A systematic comparison of kinetic modelling methods generating parametric maps for [(11)C]-(R)-PK11195. Neuroimage. 36:28-37. DOI.
  • Tai YF; Pavese N; Gerhard A; Tabrizi SJ; Barker RA; Brooks DJ; Piccini P. (30 Apr 2007). Imaging microglial activation in Huntington's disease. Brain Res Bull. 72:148-151. DOI.
  • Brooks DJ. (Jul 2007). Imaging non-dopaminergic function in Parkinson's disease. Mol Imaging Biol. 9:217-222. DOI.
  • Hammers A; Asselin MC; Hinz R; Kitchen I; Brooks DJ; Duncan JS; Koepp MJ. (Apr 2007). Upregulation of opioid receptor binding following spontaneous epileptic seizures. Brain. 130:1009-1016. DOI.
  • Turkheimer FE; Edison P; Pavese N; Roncaroli F; Anderson AN; Hammers A; Gerhard A; Hinz R; et alTai YF; Brooks DJ. (Jan 2007). Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J Nucl Med. 48:158-167.
  • Rascol O; Brooks DJ; Korczyn AD; De Deyn PP; Clarke CE; Lang AE; Abdalla M; 056 Study Grp. (Nov 2006). Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. MOVEMENT DISORD. 21:1844-1850. DOI.
  • Pavese N; Evans AH; Tai YF; Hotton G; Brooks DJ; Lees AJ; Piccini P. (14 Nov 2006). Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology. 67:1612-1617. DOI.
  • Brooks DJ. (Sep 2006). PET markers of amyloid deposition and inflammation. EUR J NEUROL. 13:305-305.
  • Edison P; Archer HA; Hinz R; Hammers A; Pavese N; Tai YF; Hotton G; Cutler D; et alFox N; Kennedy A; Rossor M; Brooks DJ. (13 Feb 2007). Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 68:501-508. DOI.
  • Brooks DJ. (Aug 2006). Dopaminergic action beyond its effects on motor function: Imaging studies. JOURNAL OF NEUROLOGY. 253:8-15. DOI.
  • Tai YF; Ahsan RL; de Yébenes JG; Pavese N; Brooks DJ; Piccini P. (Mar 2007). Characterization of dopaminergic dysfunction in familial progressive supranuclear palsy: an 18F-dopa PET study. J Neural Transm. 114:337-340. DOI.
  • Piccini P; Brooks DJ. (Dec 2006). New developments of brain imaging for Parkinson's disease and related disorders. Mov Disord. 21:2035-2041. DOI.
  • Archer HA; Edison P; Brooks DJ; Barnes J; Frost C; Yeatman T; Fox NC; Rossor MN. (Jul 2006). Amyloid load and cerebral atrophy in Alzheimer's disease: An C-11-PIB positron emission tomography study. ANN NEUROL. 60:145-147. DOI.
  • Pavese N; Gerhard A; Tai YF; Ho AK; Turkheimer F; Barker RA; Brooks DJ; Piccini P. (13 Jun 2006). Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology. 66:1638-1643. DOI.
  • Evans AH; Pavese N; Lawrence AD; Tai YF; Appel S; Doder M; Brooks DJ; Lees AJ; et alPiccini P. (May 2006). Compulsive drug use linked to sensitized ventral striatal dopamine transmission. ANN NEUROL. 59:852-858. DOI.
  • Hammers A; Chen CH; Lemieux L; Allom R; Vossos S; Free SL; Myers R; Brooks DJ; et alDuncan JS; Koepp MJ. (Jan 2007). Statistical neuroanatomy of the human inferior frontal gyrus and probabilistic atlas in a standard stereotaxic space. Hum Brain Mapp. 28:34-48. DOI.
  • Brooks DJ; Piccini P. (15 May 2006). Imaging in Parkinson's disease: the role of monoamines in behavior. Biol Psychiatry. 59:908-918. DOI.
  • Lang AE; Gill S; Patel NK; Lozano A; Nutt JG; Penn R; Brooks DJ; Hotton G; et alMoro E; Heywood P; Brodsky MA; Burchiel K; Kelly P; Dalvi A; Scott B; Stacy M; Turner D; Wooten VGF; Elias WJ; Laws ER; Dhawan V; Stoessl AJ; Matcham J; Coffey RJ; Traub M. (Mar 2006). Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. ANN NEUROL. 59:459-466. DOI.
  • Lang AE; Langston W; Stoess AJ; Brodsky M; Brooks DJ; Dhawan V; Elias WJ; Lozano AM; et alMoro E; Nutt JG; Stacy M; Turner D; Wooten GF. (Mar 2006). GDNF in treatment of Parkinson's disease: response to editorial. LANCET NEUROL. 5:200-202.
  • Scherfler C; Khan NL; Pavese N; Lees AJ; Quinn NP; Brooks DJ; Piccini PP. (Jun 2006). Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations. Mov Disord. 21:783-788. DOI.
  • Gerhard A; Pavese N; Hotton G; Turkheimer F; Es M; Hammers A; Eggert K; Oertel W; et alBanati RB; Brooks DJ. (Feb 2006). In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis. 21:404-412. DOI.
  • Goerendt IK; Lawrence AD; Mehta MA; Stern JS; Odin P; Brooks DJ. (Jan 2006). Distributed neural actions of anti-parkinsonian therapies as revealed by PET. J Neural Transm. 113:75-86. DOI.
  • Gerhard A; Trender-Gerhard I; Turkheimer F; Quinn NP; Bhatia KP; Brooks DJ. (Jan 2006). In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Mov Disord. 21:89-93. DOI.
  • Isaacs JD; Rakshi J; Baker R; Brooks DJ; Warrens AN. (Dec 2005). Chorea associated with thyroxine replacement therapy. Mov Disord. 20:1656-1657. DOI.
  • Piccini P; Pavese N; Hagell P; Reimer J; Björklund A; Oertel WH; Quinn NP; Brooks DJ; et alLindvall O. (Dec 2005). Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain. 128:2977-2986. DOI.
  • Hu MT; Scherfler C; Khan NL; Hajnal JV; Lees AJ; Quinn N; Wood NW; Brooks DJ. (Mar 2006). Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and Parkin-linked Parkinson's disease. Mov Disord. 21:299-305. DOI.
  • Turner MR; Osei-Lah AD; Hammers A; Al-Chalabi A; Shaw CE; Andersen PM; Brooks DJ; Leigh PN; et alMills KR. (Sep 2005). Abnormal cortical excitability in sporadic but not homozygous D90A SOD1 ALS. J NEUROL NEUROSUR PS. 76:1279-1285. DOI.
  • Cheesman AL; Barker RA; Lewis SJ; Robbins TW; Owen AM; Brooks DJ. (Sep 2005). Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's disease. J Neurol Neurosurg Psychiatry. 76:1204-1210. DOI.
  • Lingford-Hughes AR; Wilson SJ; Cunningham VJ; Feeney A; Stevenson B; Brooks DJ; Nutt DJ. (Aug 2005). GABA-benzodiazepine receptor function in alcohol dependence: a combined C-11-flumazenil PET and pharmacodynamic study. PSYCHOPHARMACOLOGY. 180:595-606. DOI.
  • Love S; Plaha P; Patel NK; Hotton GR; Brooks DJ; Gill SS. (Jul 2005). Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. NAT MED. 11:703-704.
  • Turner MR; Hammers A; Al-Chalabi A; Shaw CE; Andersen PM; Brooks DJ; Leigh PN. (Jun 2005). Distinct cerebral lesions in sporadic and 'D90A' SOD1 ALS: studies with [C-11]flumazenil PET. BRAIN. 128:1323-1329. DOI.
  • Turner MR; Gerhard A; Al-Chalabi A; Shaw CE; Hughes RAC; Banati RB; Brooks DJ; Leigh PN. (Jun 2005). Mills' and other isolated upper motor neurone syndromes: in vivo study with C-11-(R)-PK11195 PET. J NEUROL NEUROSUR PS. 76:871-874. DOI.
  • Hammers A; Koepp MJ; Brooks DJ; Duncan JS. (Jun 2005). Periventricular white matter flumazenil binding and postoperative outcome in hippocampal sclerosis. Epilepsia. 46:944-948. DOI.
  • Ros R; Garre PG; Hirano M; Tai YF; Ampuero I; Vidal L; Rojo A; Fontan A; et alVazquez A; Fanjul S; Hernandez J; Cantarero S; Hoenicka J; Jones A; Ahsan RL; Pavese N; Piccini P; Brooks DJ; Perez-Tur J; Nyggard T; de Yebenes JG. (May 2005). Genetic linkage of autosomal dominant progressive supranuclear palsy to 1q31.1. ANN NEUROL. 57:634-641. DOI.
  • Turner MR; Rabiner EA; Hammers A; Al-Chalabi A; Grasby PM; Shaw CE; Brooks DJ; Leigh PN. (Apr 2005). [11C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS. Brain. 128:896-905. DOI.
  • Brooks DJ. (Apr 2005). Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. NeuroRx. 2:226-236. DOI.
  • von Spiczak S; Whone AL; Hammers A; Asselin MC; Turkheimer F; Tings T; Happe S; Paulus W; et alTrenkwalder C; Brooks DJ. (Apr 2005). The role of opioids in restless legs syndrome: an [11C]diprenorphine PET study. Brain. 128:906-917. DOI.
  • Ravina B; Eidelberg D; Ahlskog JE; Albin RL; Brooks DJ; Carbon M; Dhawan V; Feigin A; et alFahn S; Guttman M; Gwinn-Hardy K; McFarland H; Innis R; Katz RG; Kieburtz K; Kish SJ; Lange N; Langston JW; Marek K; Morin L; Moy C; Murphy D; Oertel WH; Oliver G; Palesch Y; Powers W; Seibyl J; Sethi KD; Shults CW; Sheehy P; Stoessl AJ; Holloway R. (25 Jan 2005). The role of radiotracer imaging in Parkinson disease. Neurology. 64:208-215. DOI.
  • Khan NL; Scherfler C; Graham E; Bhatia KP; Quinn N; Lees AJ; Brooks DJ; Wood NW; et alPiccini P. (11 Jan 2005). Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology. 64:134-136. DOI.
  • Chaudhuri KR; Buxton-Thomas M; Dhawan V; Peng R; Meilak C; Brooks DJ. (Jan 2005). Long duration asymmetrical postural tremor is likely to predict development of Parkinson's disease and not essential tremor: clinical follow up study of 13 cases. J NEUROL NEUROSUR PS. 76:115-117. DOI.
  • Brooks DJ; Agid Y; Eggert K; Widner H; Ostergaard K; Holopainen A; TC-INIT Study Group. (2005). Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. Eur Neurol. 53:197-202. DOI.
  • Melichar JK; Hume SP; Williams TM; Daglish MRC; Taylor LG; Ahmad R; Malizia AL; Brooks DJ; et alMyles JS; Lingford-Hughes A; Nutt DJ. (Jan 2005). Using [C-11]diprenorphine to image opioid receptor occupancy by methadone in opioid addiction: Clinical and preclinical studies. J PHARMACOL EXP THER. 312:309-315. DOI.
  • Whone AL; Von Spiczak S; Edwards M; Valente EM; Hammers A; Bhatia KP; Brooks DJ. (Dec 2004). Opioid binding in DYT1 primary torsion dystonia: an 11C-diprenorphine PET study. Mov Disord. 19:1498-1503. DOI.
  • Gerhard A; Watts J; Trender-Gerhard I; Turkheimer F; Banati RB; Bhatia K; Brooks DJ. (Oct 2004). In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. Mov Disord. 19:1221-1226. DOI.
  • Brooks DJ. (Oct 2004). Positron emission tomography imaging of transplant function. NeuroRx. 1:482-491. DOI.
  • Whone AL; Bailey DL; Remy P; Pavese N; Brooks DJ. (Jul 2004). A technique for standardized central analysis of 6-(18)F-fluoro-L-DOPA PET data from a multicenter study. J Nucl Med. 45:1135-1145.
  • Scherfler C; Khan NL; Pavese N; Eunson L; Graham E; Lees AJ; Quinn NP; Wood NW; et alBrooks DJ; Piccini PP. (Jun 2004). Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain. 127:1332-1342. DOI.
  • Berding G; Muller-Vahl K; Schneider U; Gielow P; Fitschen J; Stuhrmann M; Harke H; Buchert R; et alDonnerstag F; Hofmann M; Knoop BO; Brooks DJ; Emrich HM; Knapp WH. (1 May 2004). [(123) I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Delta(9)-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in Tourette patients. BIOL PSYCHIAT. 55:904-915. DOI.
  • Brooks DJ. (Apr 2004). Neuroimaging in Parkinson's disease. NeuroRx. 1:243-254. DOI.
  • Pavese N; Rimoldi O; Gerhard A; Brooks DJ; Piccini P. (Mar 2004). Cardiovascular effects of methamphetamine in Parkinson's disease patients. Mov Disord. 19:298-303. DOI.
  • Tai YF; Scherfler C; Brooks DJ; Sawamoto N; Castiello U. (20 Jan 2004). The human premotor cortex is 'mirror' only for biological actions. Curr Biol. 14:117-120.
  • Brooks DJ. (13 Jan 2004). Safety and tolerability of COMT inhibitors. Neurology. 62:S39-S46.
  • Fern-Pollak L; Whone AL; Brooks DJ; Mehta MA. (2004). Cognitive and motor effects of dopaminergic medication withdrawal in Parkinson's disease. Neuropsychologia. 42:1917-1926. DOI.
  • Goerendt IK; Lawrence AD; Brooks DJ. (Jan 2004). Reward processing in health and Parkinson's disease: neural organization and reorganization. Cereb Cortex. 14:73-80.
  • Brooks DJ; Frey KA; Marek KL; Oakes D; Paty D; Prentice R; Shults CW; Stoessl AJ. (Nov 2003). Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. EXP NEUROL. 184:S68-S79. DOI.
  • Brooks DJ; Whone AL. (Nov 2003). Real-PET and CONSORT - Reply. ANN NEUROL. 54:692-693. DOI.
  • Gerhard A; Banati RB; Goerres GB; Cagnin A; Myers R; Gunn RN; Turkheimer F; Good CD; et alMathias CJ; Quinn N; Schwarz J; Brooks DJ. (9 Sep 2003). [11C](R)-PK11195 PET imaging of microglial activation in multiple system atrophy. Neurology. 61:686-689.
  • Moore RY; Whone AL; McGowan S; Brooks DJ. (29 Aug 2003). Monoamine neuron innervation of the normal human brain: an 18F-DOPA PET study. Brain Res. 982:137-145.
  • Brooks DJ; Sagar H; UK-Irish Entacapone Study Group. (Aug 2003). Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry. 74:1071-1079.
  • Hammers A; Allom R; Koepp MJ; Free SL; Myers R; Lemieux L; Mitchell TN; Brooks DJ; et alDuncan JS. (Aug 2003). Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 19:224-247. DOI.
  • Whone AL; Watts RL; Stoessl AJ; Davis M; Reske S; Nahmias C; Lang AE; Rascol O; et alRibeiro MJ; Remy P; Poewe WH; Hauser RA; Brooks DJ; REAL-PET Study Group. (Jul 2003). Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 54:93-101. DOI.
  • Hammers A; Koepp MJ; Richardson MP; Hurlemann R; Brooks DJ; Duncan JS. (Jun 2003). Grey and white matter flumazenil binding in neocortical epilepsy with normal MRI. A PET study of 44 patients. Brain. 126:1300-1318.
  • Brooks DJ. (Jun 2003). PET studies on the function of dopamine in health and Parkinson's disease. Ann N Y Acad Sci. 991:22-35.
  • Gill SS; Patel NK; Hotton GR; O'Sullivan K; McCarter R; Bunnage M; Brooks DJ; Svendsen CN; et alHeywood P. (May 2003). Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 9:589-595. DOI.
  • Piccini P; Pavese N; Brooks DJ. (May 2003). Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Ann Neurol. 53:647-653. DOI.
  • Pavese N; Andrews TC; Brooks DJ; Ho AK; Rosser AE; Barker RA; Robbins TW; Sahakian BJ; et alDunnett SB; Piccini P. (May 2003). Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain. 126:1127-1135.
  • Doder M; Rabiner EA; Turjanski N; Lees AJ; Brooks DJ; 11C-WAY 100635 PET study. (25 Feb 2003). Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology. 60:601-605.
  • Berding G; Brucke T; Odin P; Brooks DJ; Kolbe H; Gielow P; Harke H; Knoop BO; et alDengler R; Knapp WH. (Feb 2003). [I-123]beta-CIT SPEICT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy. NUKLEARMED-NUCL MED. 42:31-38.
  • Goerendt IK; Messa C; Lawrence AD; Grasby PM; Piccini P; Brooks DJ; PET study. (Feb 2003). Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study. Brain. 126:312-325.
  • Whone AL; Moore RY; Piccini PP; Brooks DJ. (Feb 2003). Plasticity of the nigropallidal pathway in Parkinson's disease. Ann Neurol. 53:206-213. DOI.
  • Brooks DJ. (2003). Imaging end points for monitoring neuroprotection in Parkinson's disease. ANN NEUROL. 53:S110-S118. DOI.
  • Rakshi JS; Pavese N; Uema T; Ito K; Morrish PK; Bailey DL; Brooks DJ. (Dec 2002). A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study. J Neural Transm. 109:1433-1443. DOI.
  • Khan NL; Valente EM; Bentivoglio AR; Wood NW; Albanese A; Brooks DJ; Piccini P. (Dec 2002). Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol. 52:849-853. DOI.
  • Hu MT; Chaudhuri KR; Jarosz J; Yaguez L; Brooks DJ. (Nov 2002). An imaging study of parkinsonism among African-Caribbean and Indian London communities. Mov Disord. 17:1321-1328. DOI.
  • Boecker H; Ceballos-Baumann AO; Bartenstein P; Dagher A; Forster K; Haslinger B; Brooks DJ; Schwaiger M; et alConrad B. (Oct 2002). A H(2)(15)O positron emission tomography study on mental imagery of movement sequences--the effect of modulating sequence length and direction. Neuroimage. 17:999-1009.
  • Hammers A; Koepp MJ; Hurlemann R; Thom M; Richardson MP; Brooks DJ; Duncan JS. (Oct 2002). Abnormalities of grey and white matter [11C]flumazenil binding in temporal lobe epilepsy with normal MRI. Brain. 125:2257-2271.
  • Khan NL; Brooks DJ; Pavese N; Sweeney MG; Wood NW; Lees AJ; Piccini P. (Oct 2002). Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain. 125:2248-2256.
  • Pal S; Peng R; Brooks DJ; Rao CS. (Aug 2002). Isolated asymmetric dominantly postural temor with or without resting tremor: A variant presentation of long latency tremulous Parkinson's disease? A clinical follow up. J NEUROL NEUROSUR PS. 73:215-215.
  • Hammers A; Koepp MJ; Aston JAD; Lemieux L; Richardson MP; Brooks DJ; Duncan JS. (Jul 2002). [11]C-diprenorphine PET in malformations of cortical development (MCD): voxel-based analysis and region-based partial volume effect correction. NEUROIMAGE. 16:S77-S77.
  • Hagell P; Piccini P; Björklund A; Brundin P; Rehncrona S; Widner H; Crabb L; Pavese N; et alOertel WH; Quinn N; Brooks DJ; Lindvall O. (Jul 2002). Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci. 5:627-628. DOI.
  • Lingford-Hughes A; Hume SP; Feeney A; Hirani E; Osman S; Cunningham VJ; Pike VW; Brooks DJ; et alNutt DJ. (Jul 2002). Imaging the GABA-benzodiazepine receptor subtype containing the alpha5-subunit in vivo with [11C]Ro15 4513 positron emission tomography. J Cereb Blood Flow Metab. 22:878-889. DOI.
  • Cagnin A; Brooks DJ; MacKinnon T; Banati RA. (Jul 2002). In vivo detection of activated microglia in fronto-temporal dementia. NEUROBIOL AGING. 23:S357-S358.
  • Hammers A; Allom R; Free SL; Myers R; Lemieux L; Mitchell TN; Brooks DJ; Koepp MJ; et alDuncan JS. (Jul 2002). Three-dimensional probabilistic atlas of the human brain. NEUROIMAGE. 16:S86-S86.
  • Ito K; Nagano-Saito A; Kato T; Arahata Y; Nakamura A; Kawasumi Y; Hatano K; Abe Y; et alYamada T; Kachi T; Brooks DJ. (Jun 2002). Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F]fluoro-L-dopa PET study. Brain. 125:1358-1365.
  • Brunt ER; Brooks DJ; Korczyn AD; Montastruc JL; Stocchi F; 043 Study Group. (Apr 2002). A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. J Neural Transm. 109:489-502. DOI.
  • Kjaer TW; Bertelsen C; Piccini P; Brooks D; Alving J; Lou HC. (Apr 2002). Increased dopamine tone during meditation-induced change of consciousness. Brain Res Cogn Brain Res. 13:255-259.
  • Ceravolo R; Piccini P; Bailey DL; Jorga KM; Bryson H; Brooks DJ. (1 Mar 2002). 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse. 43:201-207. DOI.
  • Daglish MRC; Lingford-Hughes A; Williams TM; Davies SJC; Melichar JK; Brooks DJ; Myles JS; Nutt DJ. (Mar 2002). A PET study of brain opioid receptor changes after withdrawal from chronic methadone treatment. EUR NEUROPSYCHOPHARM. 12:S22-S22.
  • Daglish MRC; Lingford-Hughes A; Williams T; Wilson S; Brooks DJ; Myles JS; Grasby P; Nutt DJ. (Mar 2002). A PET study testing the dopamine hypothesis in opiate dependence in humans. EUR NEUROPSYCHOPHARM. 12:S22-S23.
  • Wilson S; Lingford-Hughes A; Cunningham VJ; Gunn R; Feeney A; Stevenson BJ; Myles J; Brooks DJ; et alNutt DJ. (Mar 2002). Assessing the function of the GABA-benzodiazepine receptor in alcohol dependence using PET and EEG. EUR NEUROPSYCHOPHARM. 12:S21-S21.
  • Brooks DJ. (Mar 2002). Diagnosis and management of atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 72 Suppl 1:I10-I16.
  • Lingford-Hughes A; Hume SP; Feeney A; Hirani E; Osman S; Cunningham VJ; Pike VW; Brooks DJ; et alNutt DJ. (Mar 2002). Imaging in vivo the GABA-benzodiazepine receptor containing the alpha 5 subunit in man and rat. EUR NEUROPSYCHOPHARM. 12:S20-S20.
  • Hammers A; Koepp MJ; Free SL; Brett M; Richardson MP; Labbé C; Cunningham VJ; Brooks DJ; et alDuncan J. (Mar 2002). Implementation and application of a brain template for multiple volumes of interest. Hum Brain Mapp. 15:165-174.
  • Khan NL; Brooks DJ; Pavese N; Wood NW; Lees AJ; Piccini P. (Jan 2002). Progression of nigrostriatal dysfunction in a parkin kindred: An F-18-dopa PET and clinical study. J NEUROL NEUROSUR PS. 72:134-134.
  • Nicholl DJ; Vaughan JR; Khan NL; Ho SL; Aldous DE; Lincoln S; Farrer M; Gayton JD; et alDavis MB; Piccini P; Daniel SE; Lennox GG; Brooks DJ; Williams AC; Wood NW. (Jan 2002). Two large British kindreds with familial Parkinson's disease: a clinico-pathological and genetic study. Brain. 125:44-57.
  • Hirani E; Gillies J; Karasawa A; Shimada J; Kase H; Opacka-Juffry J; Osman S; Luthra SK; et alHume SP; Brooks DJ. (1 Dec 2001). Evaluation of [4-O-methyl-(11)C]KW-6002 as a potential PET ligand for mapping central adenosine A(2A) receptors in rats. Synapse. 42:164-176. DOI.
  • Banati RB; Cagnin A; Brooks DJ; Gunn RN; Myers R; Jones T; Birch R; Anand P. (16 Nov 2001). Long-term trans-synaptic glial responses in the human thalamus after peripheral nerve injury. Neuroreport. 12:3439-3442.
  • Piccini P; de Yebenez J; Lees AJ; Ceravolo R; Turjanski N; Pramstaller P; Brooks DJ. (Nov 2001). Familial progressive supranuclear palsy: detection of subclinical cases using 18F-dopa and 18fluorodeoxyglucose positron emission tomography. Arch Neurol. 58:1846-1851.
  • Berding G; Odin P; Brooks DJ; Nikkhah G; Matthies C; Peschel T; Shing M; Kolbe H; et alvan Den Hoff J; Fricke H; Dengler R; Samii M; Knapp WH. (Nov 2001). Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in the off and on conditions with [(18)F]FDG-PET. Mov Disord. 16:1014-1022.
  • Richardson MP; Hammers A; Brooks DJ; Duncan JS. (Oct 2001). Benzodiazepine-GABA(A) receptor binding is very low in dysembryoplastic neuroepithelial tumor: a PET study. Epilepsia. 42:1327-1334.
  • Cagnin A; Brooks DJ; Kennedy AM; Gunn RN; Myers R; Turkheimer FE; Jones T; Banati RB. (11 Aug 2001). In-vivo measurement of activated microglia in dementia. Lancet. 358:461-467. DOI.
  • Hammers A; Koepp MJ; Richardson MP; Labbé C; Brooks DJ; Cunningham VJ; Duncan JS. (Aug 2001). Central benzodiazepine receptors in malformations of cortical development: A quantitative study. Brain. 124:1555-1565.
  • Brooks DJ; Doder M. (Aug 2001). Depression in Parkinson's disease. Curr Opin Neurol. 14:465-470.
  • Ito K; Nagano-Saito A; Kato T; Arahata Y; Nakamura A; Kawasumi Y; Hatano K; Abe Y; et alYamada T; Kachi T; Brooks DJ. (Aug 2001). Striatal and extrastriatal dysfunction in Parkinson's disease with dementia. A 6-[18F]fluoro-l-dopa PET study. EUR J NUCL MED. 28:1089-1089.
  • Bhatia K; Brooks DJ; Burn DJ; Clarke CE; Grosset DG; MacMahon DG; Playfer J; Schapira AH; et alStewart D; Williams AC; Parkinson's Disease Consensus Working Group. (Aug 2001). Updated guidelines for the management of Parkinson's disease. Hosp Med. 62:456-470.
  • Goerendt IK; Messa C; Lawrence AD; Piccini P; Grasby PM; Brooks DJ. (Jun 2001). Endogenous dopamine release during sequential movement in healthy volunteers and patients with Parkinson's disease: a PET study. NEUROIMAGE. 13:S1172-S1172.
  • Hu MT; White SJ; Herlihy AH; Chaudhuri KR; Hajnal JV; Brooks DJ. (8 May 2001). A comparison of (18)F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease. Neurology. 56:1195-1200.
  • Berding G; Klinge P; Brinker T; Weckesser E; Brooks DJ; Van Den Hoff J; Samii M; Knapp WH. (May 2001). An (H2O)-O-15-PET study of chronic hydrocephalus before and after ventriculoperitoneal shunting. J NUCL MED. 42:145P-146P.
  • Berding G; Odin P; Brooks DJ; Nikkhah G; Fricke H; Dengler R; Samii M; Knapp WH. (May 2001). An F-18-FDG-PET study of changes in cerebral resting glucose metabolism in Parkinson's disease due to L-dopa and subthalamic nucleus stimulation. J NUCL MED. 42:144P-144P.
  • Boecker H; Ceballos-Baumann AO; Forster K; Bartenstein P; Dagher A; Haslinger B; Brooks DJ; Schwaiger M; et alConrad B. (May 2001). The functional anatomy of motor sequence imagery. J NUCL MED. 42:219P-219P.
  • Dagher A; Owen AM; Boecker H; Brooks DJ. (May 2001). The role of the striatum and hippocampus in planning: a PET activation study in Parkinson's disease. Brain. 124:1020-1032.
  • Hammers A; Koepp MJ; Labbé C; Brooks DJ; Thom M; Cunningham VJ; Duncan JS. (10 Apr 2001). Neocortical abnormalities of [11C]-flumazenil PET in mesial temporal lobe epilepsy. Neurology. 56:897-906.
  • Samuel M; Ceballos-Baumann AO; Boecker H; Brooks DJ. (26 Mar 2001). Motor imagery in normal subjects and Parkinson's disease patients: an H215O PET study. Neuroreport. 12:821-828.
  • Brooks DJ. (Mar 2001). Treatment of early onset Parkinson's disease with ropinirole - Reply. J NEUROL NEUROSUR PS. 70:418-419.
  • Banati RB; Cagnin A; Birch R; Brooks DJ; Anand P. (Feb 2001). [C-11] (R)-PK11195 PET shows long term trans-synaptic remodelling in human CNS after peripheral nerve injury. J NEUROL NEUROSUR PS. 70:275-275.
  • Brooks DJ. (2001). Cerebral blood flow activation studies in Parkinson's disease. Adv Neurol. 86:225-235.
  • Hu MT; White SJ; Chaudhuri KR; Morris RG; Bydder GM; Brooks DJ. (2001). Correlating rates of cerebral atrophy in Parkinson's disease with measures of cognitive decline. J Neural Transm. 108:571-580.
  • Brooks DJ. (2001). Functional imaging studies on dopamine and motor control. J Neural Transm. 108:1283-1298.
  • Piccini P; Lindvall O; Björklund A; Brundin P; Hagell P; Ceravolo R; Oertel W; Quinn N; et alSamuel M; Rehncrona S; Widner H; Brooks DJ. (Nov 2000). Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol. 48:689-695.
  • Lloyd CM; Richardson MP; Brooks DJ; Al-Chalabi A; Leigh PN. (Nov 2000). Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C]flumazenil. Brain. 123 ( Pt 11):2289-2296.
  • Brooks DJ. (Oct 2000). PET studies and motor complications in Parkinson's disease. Trends Neurosci. 23:S101-S108.
  • White RP; Deane C; Hindley C; Bloomfield PM; Cunningham VJ; Vallance P; Brooks DJ; Markus HS. (Sep 2000). The effect of the nitric oxide donor glyceryl trinitrate on global and regional cerebral blood flow in man. J NEUROL SCI. 178:23-28.
  • Capaday C; Richardson MP; Rothwell JC; Brooks DJ. (Aug 2000). Long-term changes of GABAergic function in the sensorimotor cortex of amputees - A combined magnetic stimulation and C-11-flumazenil PET study. EXP BRAIN RES. 133:552-556.
  • Brundin P; Pogarell O; Hagell P; Piccini P; Widner H; Schrag A; Kupsch A; Crabb L; et alOdin P; Gustavii B; Bjorklund A; Brooks DJ; Marsden CD; Oertel WH; Quinn NP; Rehncrona S; Lindvall O. (Jul 2000). Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. BRAIN. 123:1380-1390.
  • Brooks DJ. (Jun 2000). Dopamine agonists: their role in the treatment of Parkinson's disease. J NEUROL NEUROSUR PS. 68:685-689.
  • Jenkins IH; Jahanshahi M; Jueptner M; Passingham RE; Brooks DJ. (Jun 2000). Self-initiated versus externally triggered movements II. The effect of movement predictability on regional cerebral blood flow. BRAIN. 123:1216-1228.
  • Brooks DJ. (May 2000). Imaging basal ganglia function. J Anat. 196 ( Pt 4):543-554.
  • Piccini P; Brooks DJ; Korpela K; Pavese N; Karlsson M; Gordin A. (May 2000). The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry. 68:589-594.
  • Lingford-Hughes AR; Cunningham VJ; Feeney AJ; Wilson SJ; Gunn RN; Stephenson B; Brooks DJ; Nutt DJ. (May 2000). The function of the GABA-benzodiazepine receptor in alcohol dependence. J NUCL MED. 41:136P-136P.
  • Jalan R; Turjanski N; Taylor-Robinson SD; Koepp MJ; Richardson MP; Wilson JA; Bell JD; Brooks DJ. (Apr 2000). Increased availability of central benzodiazepine receptors in patients with chronic hepatic encephalopathy and alcohol related cirrhosis. Gut. 46:546-552.
  • Brooks DJ. (Apr 2000). Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease. J Neurol. 247 Suppl 2:II11-II18.
  • Brooks DJ; Piccini P; Turjanski N; Samuel M. (Apr 2000). Neuroimaging of dyskinesia. ANNALS OF NEUROLOGY. 47:S154-S159.
  • Brooks DJ; Forsyth D; Playfer JR; Williams AC. (Apr 2000). The role of entacapone in the management of Parkinson's disease. Hosp Med. 61:267-271.
  • Hagell P; Crabb L; Pogarell O; Schrag A; Widner H; Brooks DJ; Oertel WH; Quinn NP; et alLindvall O. (Mar 2000). Health-related quality of life following bilateral intrastriatal transplantation in Parkinson's disease. MOVEMENT DISORD. 15:224-229.
  • Hu MTM; Taylor-Robinson SD; Chaudhuri KR; Bell JD; Labbe C; Cunningham VJ; Koepp MJ; Hammers A; et alMorris RG; Turjanski N; Brooks DJ. (Feb 2000). Cortical dysfunction in non-demented Parkinson's disease patients - A combined P-31-MRS and (18)FDG-PET study. BRAIN. 123:340-352.
  • Reuter I; Hu MTM; Andrews TC; Brooks DJ; Clough C; Chaudhuri KR. (Feb 2000). Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome. J NEUROL NEUROSUR PS. 68:238-241.
  • Brooks DJ; Lambotharan S; Chambers JA. (Feb 2000). Optimum delay and mean square error using a mixed crosscorrelation and constant modulus algorithm. IEE P-COMMUN. 147:18-22.
  • Koepp MJ; Hammers A; Labbé C; Woermann FG; Brooks DJ; Duncan JS. (25 Jan 2000). 11C-flumazenil PET in patients with refractory temporal lobe epilepsy and normal MRI. Neurology. 54:332-339.
  • Chaudhuri KR; Hu MTM; Brooks DJ. (Jan 2000). Atypical parkinsonism in Afro-Caribbean and Indian origin immigrants to the UK. MOVEMENT DISORD. 15:18-23.
  • Brooks DJ. (2000). Functional imaging studies in corticobasal degeneration. Adv Neurol. 82:209-215.
  • Brooks DJ. (2000). Monitoring neuroprotection and restorative therapies in Parkinson's disease with PET. J Neural Transm Suppl. 125-137.
  • Brooks DJ; Piccini P. (2000). Non-invasive in vivo imaging of transplant function. Prog Brain Res. 127:321-332.
  • Brooks DJ; Samuel M. (2000). The effects of surgical treatment of Parkinson's disease on brain function: PET findings. Neurology. 55:S52-S59.
  • Banati RB; Goerres GW; Myers R; Gunn RN; Turkheimer FE; Kreutzberg GW; Brooks DJ; Jones T; et alDuncan JS. (10 Dec 1999). [11C](R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen's encephalitis. Neurology. 53:2199-2203.
  • Piccini P; Brooks DJ; Björklund A; Gunn RN; Grasby PM; Rimoldi O; Brundin P; Hagell P; et alRehncrona S; Widner H; Lindvall O. (Dec 1999). Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci. 2:1137-1140. DOI.
  • Andrews TC; Weeks RA; Turjanski N; Gunn RN; Watkins LH; Sahakian B; Hodges JR; Rosser AE; et alWood NW; Brooks DJ. (Dec 1999). Huntington's disease progression. PET and clinical observations. Brain. 122 ( Pt 12):2353-2363.
  • Dagher A; Owen AM; Boecker H; Brooks DJ. (Oct 1999). Mapping the network for planning: a correlational PET activation study with the Tower of London task. BRAIN. 122:1973-1987.
  • Schrag A; Samuel M; Caputo E; Scaravilli T; Troyer M; Marsden CD; Thomas DGT; Lees AJ; et alBrooks DJ; Quinn NP. (Oct 1999). Unilateral pallidotomy for Parkinson's disease: results after more than 1 year. J NEUROL NEUROSUR PS. 67:511-517.
  • Rakshi JS; Uema T; Ito K; Bailey DL; Morrish PK; Ashburner J; Dagher A; Jenkins IH; et alFriston KJ; Brooks DJ. (Sep 1999). Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease - A 3D [F-18]dopa-PET study. BRAIN. 122:1637-1650.
  • Hu MT; Taylor-Robinson SD; Chaudhuri KR; Bell JD; Morris RG; Clough C; Brooks DJ; Turjanski N. (Jul 1999). Evidence for cortical dysfunction in clinically non-demented patients with Parkinson's disease: a proton MR spectroscopy study. J Neurol Neurosurg Psychiatry. 67:20-26.
  • Hagell P; Schrag A; Piccini P; Jahanshahi M; Brown R; Rehncrona S; Widner H; Brundin P; et alRothwell JC; Odin P; Wenning GK; Morrish P; Gustavii B; Bjorklund A; Brooks DJ; Marsden CD; Quinn NP; Lindvall O. (Jun 1999). Sequential bilateral transplantation in Parkinson's disease - Effects of the second graft. BRAIN. 122:1121-1132.
  • Ito K; Morrish PK; Rakshi JS; Uema T; Ashburner J; Bailey DL; Friston KJ; Brooks DJ. (Jun 1999). Statistical parametric mapping with 18F-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in early Parkinson's disease. J Neurol Neurosurg Psychiatry. 66:754-758.
  • White RP; Hindley C; Bloomfield PM; Cunningham VJ; Vallance P; Brooks DJ; Markus HS. (Jun 1999). The effect of the nitric oxide synthase inhibitor L-NMMA on basal CBF and vasoneuronal coupling in man: a PET study. J CEREBR BLOOD F MET. 19:673-678.
  • Nicolson RI; Fawcett AJ; Berry EL; Jenkins IH; Dean P; Brooks DJ. (15 May 1999). Association of abnormal cerebellar activation with motor learning difficulties in dyslexic adults. LANCET. 353:1662-1667.
  • Piccini P; Burn DJ; Ceravolo R; Maraganore D; Brooks DJ. (May 1999). The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol. 45:577-582.
  • McGowan SW; Bailey D; Brooks DJ; Grasby PM. (Apr 1999). Can cortical presynaptic dopaminergic function be measured in vivo?. SCHIZOPHR RES. 36:244-244.
  • Hamdy S; Rothwell JC; Brooks DJ; Bailey D; Aziz Q; Thompson DG. (Apr 1999). Identification of the cerebral loci processing human swallowing with H-2 O-15 PET activation. J NEUROPHYSIOL. 81:1917-1926.
  • McGowan SW; Lawrence AD; Bridger E; Grasby PM; Brooks DJ; Bench CJ. (Apr 1999). Probabilistic classification learning in people with schizophrenia. SCHIZOPHR RES. 36:176-177.
  • Turjanski N; Lees AJ; Brooks DJ. (23 Mar 1999). Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology. 52:932-937.
  • Taylor-Robinson SD; Turjanski N; Bhattacharya S; Seery JP; Sargentoni J; Brooks DJ; Bryant DJ; Cox IJ. (Mar 1999). A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease. Metab Brain Dis. 14:45-55.
  • Piccini P; Brooks DJ. (1999). Etiology of Parkinson's disease: contributions from 18F-DOPA positron emission tomography. Adv Neurol. 80:227-231.
  • Brooks DJ. (1999). Functional imaging of Parkinson's disease: is it possible to detect brain areas for specific symptoms?. JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT. 139-153.
  • Hammers A; Richardson MP; Koepp MJ; Labb C; Brooks DJ; Cunningham VJ; Duncant JS. (1999). Partial volume effect corrected [11C] Flumazenil pet in malformations of cortical development. EPILEPSIA. 40:217-217.
  • Kapur N; Brooks DJ. (1999). Temporally-specific retrograde amnesia in two cases of discrete bilateral hippocampal pathology. HIPPOCAMPUS. 9:247-254.
  • Andrews TC; Brooks DJ. (Dec 1998). Advances in the understanding of early Huntington's disease using the functional imaging techniques of PET and SPET. Mol Med Today. 4:532-539.
  • Samuel M; Williams SC; Leigh PN; Simmons A; Chakraborti S; Andrew CM; Friston KJ; Goldstein LH; et alBrooks DJ. (Dec 1998). Exploring the temporal nature of hemodynamic responses of cortical motor areas using functional MRI. Neurology. 51:1567-1575.
  • Goerres GW; Samuel M; Jenkins IH; Brooks DJ. (16 Nov 1998). Cerebral control of unimanual and bimanual movements: an (H2O)-O-15 PET study. NEUROREPORT. 9:3631-3638.
  • Koepp MJ; Richardson MP; Brooks DJ; Duncan JS. (19 Sep 1998). Focal cortical release of endogenous opioids during reading-induced seizures. Lancet. 352:952-955.
  • Brooks DJ. (Sep 1998). The early diagnosis of Parkinson's disease. Ann Neurol. 44:S10-S18.
  • Richardson MP; Koepp MJ; Brooks DJ; Duncan JS. (Aug 1998). 11C-flumazenil PET in neocortical epilepsy. Neurology. 51:485-492.
  • Richardson MP; Koepp MJ; Brooks DJ; Coull JT; Grasby P; Fish DR; Duncan JS. (Jul 1998). Cerebral activation in malformations of cortical development. BRAIN. 121:1295-1304.
  • Schrag A; Rinne JO; Burn DJ; Mathias CJ; Marsden CD; Brooks DJ; Quinn NP. (Jul 1998). Olivopontocerebellar atrophy and multiple system atrophy: Clinical follow-up of 10 patients studied with PET. ANN NEUROL. 44:151-152.
  • Lawrence AD; Weeks RA; Brooks DJ; Andrews TC; Watkins LHA; Harding AE; Robbins TW; Sahakian BJ. (Jul 1998). The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease. BRAIN. 121:1343-1355.
  • Bhatia K; Brooks DJ; Burn DJ; Clarke CE; Playfer J; Sawle GV; Schapira AHV; Stewart D; et alWilliams AC; Parkinson Dis Consensus Working Grp. (Jun 1998). Guidelines for the management of Parkinson's disease. HOSP MED. 59:469-480.
  • Koepp MJ; Gunn RN; Lawrence AD; Cunningham VJ; Dagher A; Jones T; Brooks DJ; Bench CJ; et alGrasby PM. (21 May 1998). Evidence for striatal dopamine release during a video game. Nature. 393:266-268. DOI.
  • Koepp MJ; Hand KS; Labbé C; Richardson MP; Van Paesschen W; Baird VH; Cunningham VJ; Bowery NG; et alBrooks DJ; Duncan JS. (May 1998). In vivo [11C]flumazenil-PET correlates with ex vivo [3H]flumazenil autoradiography in hippocampal sclerosis. Ann Neurol. 43:618-626. DOI.
  • Schrag AE; Brooks DJ; Brunt E; Fuell D; Korczyn A; Poewe W; Quinn NP; Rascol O; et alStocchi F. (May 1998). The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease. CLIN NEUROPHARMACOL. 21:169-175.
  • Hamdy S; Rothwell JC; Brooks DJ; Aziz Q; Thompson DG. (15 Apr 1998). Identification of the cerebral loci processing human swallowing function: A H2O15 PET activation study. GASTROENTEROLOGY. 114:A760-A760.
  • Samuel M; Brooks DJ. (Apr 1998). Evidence for lateral premotor and parietal overactivity in Parkinson's disease during sequential and bimanual movements. A PET study - Reply. BRAIN. 121:771-772.
  • Samuel M; Ceballos-Baumann AO; Turjanski N; Boecker H; Gorospe A; Linazasoro G; Holmes AP; DeLong MR; et alVitek JL; Bakay RAE; Thomas DGT; Quinn NP; Obeso JA; Brooks DJ. (Apr 1998). Pallidotomy in Parkinson's disease increases supplementary motor area and prefrontal activation during performance of volitional movements. An (H2O)-O-15 PET study (vol 120, pg 1301, 1997). BRAIN. 121:779-779.
  • Brooks DJ. (Apr 1998). Positron emission tomography studies in movement disorders. NEUROSURG CLIN N AM. 9:263-+.
  • Brooks DJ. (Apr 1998). Positron emission tomography studies in movement disorders. Neurosurg Clin N Am. 9:263-282.
  • Spence SA; Hirsch SR; Brooks DJ; Grasby PM. (Apr 1998). Prefrontal cortex activity in people with schizophrenia and control subjects. Evidence from positron emission tomography for remission of 'hypofrontality' with recovery from acute schizophrenia. Br J Psychiatry. 172:316-323.
  • Brooks DJ; Abbott RJ; Lees AJ; Martignoni E; Philcox DV; Rascol O; Roos RA; Sagar HJ. (Mar 1998). A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. Clin Neuropharmacol. 21:101-107.
  • Hamdy S; Rothwell JC; Brooks DJ; Aziz Q; Thompson DG. (Mar 1998). Identification of the cerebral loci processing human swallowing function: A H2O15 PET activation study. GUT. 42:A17-A17.
  • Playford ED; Passingham RE; Marsden CD; Brooks DJ. (Mar 1998). Increased activation of frontal areas during arm movement in idiopathic torsion dystonia. Mov Disord. 13:309-318. DOI.
  • Morrish PK; Rakshi JS; Bailey DL; Sawle GV; Brooks DJ. (Mar 1998). Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry. 64:314-319.
  • Koepp MJ; Hansen ML; Pressler RM; Brooks DJ; Brandl U; Guldin B; Duncan JS; Ried S. (Feb 1998). Comparison of EEG, MRI and PET in reading epilepsy: a case report. EPILEPSY RES. 29:251-257.
  • Boecker H; Dagher A; Ceballos-Baumann AO; Passingham RE; Samuel M; Friston KJ; Poline J; Dettmers C; et alConrad B; Brooks DJ. (Feb 1998). Role of the human rostral supplementary motor area and the basal ganglia in motor sequence control: investigations with H2 15O PET. J Neurophysiol. 79:1070-1080.
  • Samuel M; Caputo E; Brooks DJ; Schrag A; Scaravilli T; Branston NM; Rothwell JC; Marsden CD; et alThomas DG; Lees AJ; Quinn NP. (Jan 1998). A study of medial pallidotomy for Parkinson's disease: clinical outcome, MRI location and complications. Brain. 121 ( Pt 1):59-75.
  • Ceballos-Baumann AO; Brooks DJ. (1998). Activation positron emission tomography scanning in dystonia. Adv Neurol. 78:135-152.
  • Boecker H; Brooks DJ. (1998). Functional imaging of tremor. MOVEMENT DISORDERS. 13:64-72.
  • Spence SA; Hirsch SR; Brooks DJ; Grasby PM. (Jan 1998). Hypofrontality remits with schizophrenic recovery. SCHIZOPHR RES. 29:109-109.
  • Korczyn AD; Brooks DJ; Brunt ER; Poewe WH; Rascol O; Stocchi F; 056 Study Grp. (Jan 1998). Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study. MOVEMENT DISORD. 13:46-51.
  • Morrish PK; Rakshi JS; Brooks DJ. (Dec 1997). Can the neuroprotective efficacy of an agent ever be conclusively proven?. EUR J NEUROL. 4:S19-S24.
  • Spence SA; Brooks DJ; Hirsch SR; Liddle PF; Meehan J; Grasby PM. (Nov 1997). A PET study of voluntary movement in schizophrenic patients experiencing passivity phenomena (delusions of alien control). Brain. 120 ( Pt 11):1997-2011.
  • Piccini P; Weeks RA; Brooks DJ. (Nov 1997). Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol. 42:720-726. DOI.
  • Richardson MP; Friston KJ; Sisodiya SM; Koepp MJ; Ashburner J; Free SL; Brooks DJ; Duncan JS. (Nov 1997). Cortical grey matter and benzodiazepine receptors in malformations of cortical development - A voxel-based comparison of structural and functional imaging data. BRAIN. 120:1961-1973.
  • Turjanski N; Pentland B; Lees AJ; Brooks DJ. (Nov 1997). Parkinsonism associated with acute intracranial hematomas: an [18F]dopa positron-emission tomography study. Mov Disord. 12:1035-1038. DOI.
  • Jenkins IH; Passingham RE; Brooks DJ. (22 Oct 1997). The effect of movement frequency on cerebral activation: a positron emission tomography study. J Neurol Sci. 151:195-205.
  • Koepp MJ; Richardson MP; Brooks DJ; Cunningham VJ; Duncan JS. (Oct 1997). Central benzodiazepine/gamma-aminobutyric acid A receptors in idiopathic generalized epilepsy: an [11C]flumazenil positron emission tomography study. Epilepsia. 38:1089-1097.
  • Koepp MJ; Labbé C; Richardson MP; Brooks DJ; Van Paesschen W; Cunningham VJ; Duncan JS. (Oct 1997). Regional hippocampal [11C]flumazenil PET in temporal lobe epilepsy with unilateral and bilateral hippocampal sclerosis. Brain. 120 ( Pt 10):1865-1876.
  • Weeks RA; Cunningham VJ; Piccini P; Waters S; Harding AE; Brooks DJ. (Sep 1997). 11C-diprenorphine binding in Huntington's disease: a comparison of region of interest analysis with statistical parametric mapping. J Cereb Blood Flow Metab. 17:943-949. DOI.
  • Koepp MJ; Richardson MP; Labbé C; Brooks DJ; Cunningham VJ; Ashburner J; Van Paesschen W; Revesz T; et alDuncan JS. (Sep 1997). 11C-flumazenil PET, volumetric MRI, and quantitative pathology in mesial temporal lobe epilepsy. Neurology. 49:764-773.
  • Nagahama Y; Fukuyama H; Turjanski N; Kennedy A; Yamauchi H; Ouchi Y; Kimura J; Brooks DJ; et alShibasaki H. (Sep 1997). Cerebral glucose metabolism in corticobasal degeneration: Comparison with progressive supranuclear palsy and normal controls. MOVEMENT DISORD. 12:691-696.
  • Weeks RA; Ceballos-Baumann A; Piccini P; Boecker H; Harding AE; Brooks DJ. (Sep 1997). Cortical control of movement in Huntington's disease. A PET activation study. Brain. 120 ( Pt 9):1569-1578.
  • Turjanski N; Lees AJ; Brooks DJ. (Sep 1997). In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology. 49:717-723.
  • Brooks DJ. (Aug 1997). Advances in imaging Parkinson's disease: Editorial review. CURR OPIN NEUROL. 10:327-331.
  • Samuel M; Ceballos-Baumann AO; Turjanski N; Boecker H; Gorospe A; Linazasoro G; Holmes AP; DeLong MR; et alVitek JL; Thomas DG; Quinn NP; Obeso JA; Brooks DJ. (Aug 1997). Pallidotomy in Parkinson's disease increases supplementary motor area and prefrontal activation during performance of volitional movements an H2(15)O PET study. Brain. 120 ( Pt 8):1301-1313.
  • Fricker RA; Torres EM; Hume SP; Myers R; OpackaJuffrey J; Ashworth S; Brooks DJ; Dunnett SB. (Aug 1997). The effects of donor stage on the survival and function of embryonic striatal grafts in the adult rat brain .2. Correlation between positron emission tomography and reaching behaviour. NEUROSCIENCE. 79:711-721.
  • Turjanski N; Lees AJ; Brooks DJ. (Jul 1997). Dopaminergic function in patients with posttraumatic parkinsonism: an 18F-dopa PET study. Neurology. 49:183-189.
  • Samuel M; CeballosBaumann AO; Blin J; Uema T; Boecker H; Passingham RE; Brooks DJ. (Jun 1997). Evidence for lateral premotor and parietal overactivity in Parkinson's disease during sequential and bimanual movements - A PET study. BRAIN. 120:963-976.
  • Kew JJ; Halligan PW; Marshall JC; Passingham RE; Rothwell JC; Ridding MC; Marsden CD; Brooks DJ. (May 1997). Abnormal access of axial vibrotactile input to deafferented somatosensory cortex in human upper limb amputees. J Neurophysiol. 77:2753-2764.
  • Abrahams S; Goldstein LH; AlChalabi A; Pickering A; Morris RG; Passingham RE; Brooks DJ; Leigh PN. (May 1997). Relation between cognitive dysfunction and pseudobulbar palsy in amyotrophic lateral sclerosis. J NEUROL NEUROSUR PS. 62:464-472.
  • CeballosBaumann AO; Sheean G; Passingham RE; Marsden CD; Brooks DJ. (Apr 1997). Botulinum toxin does not reverse the cortical dysfunction associated with writer's cramp - A PET study. BRAIN. 120:571-582.
  • Brooks DJ. (Apr 1997). PET and SPECT studies in Parkinson's disease. Baillieres Clin Neurol. 6:69-87.
  • Jueptner M; Stephan KM; Frith CD; Brooks DJ; Frackowiak RSJ; Passingham RE. (Mar 1997). Anatomy of motor learning .1. Frontal cortex and attention to action. J NEUROPHYSIOL. 77:1313-1324.
  • Jueptner M; Frith CD; Brooks DJ; Frackowiak RSJ; Passingham RE. (Mar 1997). Anatomy of motor learning .2. Subcortical structures and learning by trial and error. J NEUROPHYSIOL. 77:1325-1337.
  • Piccini P; Morrish PK; Turjanski N; Sawle GV; Burn DJ; Weeks RA; Mark MH; Maraganore DM; et alLees AJ; Brooks DJ. (Feb 1997). Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa positron emission tomography study. Ann Neurol. 41:222-229. DOI.
  • Ceballos-Baumann AO; Brooks DJ. (1997). Basal ganglia function and dysfunction revealed by PET activation studies. ADV NEUROL. 74:127-139.
  • Chaudhuri KR; Richards M; Brooks DJ. (Jan 1997). How far are we in understanding the cause of Parkinson's disease?. J NEUROL NEUROSUR PS. 62:104-104.
  • Turjanski N; Brooks DJ. (1997). PET and the investigation of dementia in the parkinsonian patient. J Neural Transm Suppl. 51:37-48.
  • Boecker H; Wills AJ; Ceballos-Baumann A; Samuel M; Thomas DG; Marsden CD; Brooks DJ. (Jan 1997). Stereotactic thalamotomy in tremor-dominant Parkinson's disease: an H2(15)O PET motor activation study. Ann Neurol. 41:108-111. DOI.
  • Abrahams S; Goldstein LH; Kew JJM; Brooks DJ; Lloyd CM; Frith CD; Leigh PN. (Dec 1996). Frontal lobe dysfunction in amyotrophic lateral sclerosis - A PET study. BRAIN. 119:2105-2120.
  • Morrish PK; Sawle GV; Brooks DJ. (Dec 1996). Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease. Brain. 119 ( Pt 6):2097-2103.
  • Boecker H; Brooks DJ. (Dec 1996). Specificity of ethanol in essential tremor - Reply. ANN NEUROL. 40:950-951.
  • Jueptner M; Jenkins IH; Brooks DJ; Frackowiak RS; Passingham RE. (Dec 1996). The sensory guidance of movement: a comparison of the cerebellum and basal ganglia. Exp Brain Res. 112:462-474.
  • Koepp MJ; Richardson MP; Brooks DJ; Poline JB; VanPaesschen W; Friston KJ; Duncan JS. (Oct 1996). Cerebral benzodiazepine receptors in hippocampal sclerosis - An objective in vivo analysis. BRAIN. 119:1677-1687.
  • Richardson MP; Koepp MJ; Brooks DJ; Fish DR; Duncan JS. (Aug 1996). Benzodiazepine receptors in focal epilepsy with cortical dysgenesis: An C-11-flumazenil PET study. ANN NEUROL. 40:188-198.
  • OpackaJuffry J; Brooks DJ. (Jul 1996). DOPA decarboxylase - Reply. MOVEMENT DISORD. 11:463-463.
  • Weeks RA; Piccini P; Harding AE; Brooks DJ. (Jul 1996). Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol. 40:49-54. DOI.
  • Jahanshahi M; Jenkins H; Brown RG; Marsden CD; Passingham RE; Brooks DJ. (Jun 1996). Self-initiated versus externally triggered movements .1. An investigation using measurement of regional cerebral blood flow with PET and movement-related potentials in normal and Parkinson's disease subjects - Reply. BRAIN. 119:1046-1048.
  • Weeks RA; Turjanski N; Brooks DJ. (Jun 1996). Tourette's syndrome: a disorder of cingulate and orbitofrontal function?. QJM. 89:401-408.
  • Bain PG; Britton TC; Jenkins IH; Thompson PD; Rothwell JC; Thomas PK; Brooks DJ; Marsden CD. (Jun 1996). Tremor associated with benign IgM paraproteinaemic neuropathy. BRAIN. 119:789-799.
  • Lammertsma AA; Turjanski N; Hume SP; Luthra SK; Osman S; Piccini P; Brown DJ; Carroll FI; et alBrooks DJ. (May 1996). Quantification of dopamine transporter studies using carbon-11 labelled RTI-121 and PET. J NUCL MED. 37:426-426.
  • Ito K; Rakshi JS; Uema T; Ashburner J; Morrish PK; Bailey DL; Friston KJ; Brooks DJ. (May 1996). Statistical parametric mapping of F-18-DOPA PET. J NUCL MED. 37:1213-1213.
  • Boecker H; Wills AJ; Ceballos-Baumann A; Samuel M; Thompson PD; Findley LJ; Brooks DJ. (May 1996). The effect of ethanol on alcohol-responsive essential tremor: a positron emission tomography study. Ann Neurol. 39:650-658. DOI.
  • Morrish PK; Sawle GV; Brooks DJ. (Apr 1996). An [F-18]dopa-PET and clinical study of the rate of progression in Parkinson's disease. BRAIN. 119:585-591.
  • Hume SP; Luthra SK; Brown DJ; Opacka-Juffry J; Osman S; Ashworth S; Myers R; Brady F; et alCarroll FI; Kuhar MJ; Brooks DJ. (Apr 1996). Evaluation of [11C]RTI-121 as a selective radioligand for PET studies of the dopamine transporter. Nucl Med Biol. 23:377-384.
  • Wills AJ; Thompson PD; Findley LJ; Brooks DJ. (Mar 1996). A positron emission tomography study of primary orthostatic tremor. Neurology. 46:747-752.
  • Taylor-Robinson SD; Weeks RA; Bryant DJ; Sargentoni J; Marcus CD; Harding AE; Brooks DJ. (Mar 1996). Proton magnetic resonance spectroscopy in Huntington's disease: evidence in favour of the glutamate excitotoxic theory. Mov Disord. 11:167-173. DOI.
  • Bhatia KP; Turjanski N; Brooks DJ; Marsden CD; Thrush D. (Mar 1996). The usefulness of functional imaging in movement disorders: An illustrative case. J NEUROL NEUROSUR PS. 60:353-354.
  • Weeks RA; Scott J; Brooks DJ; Hodgson H; Cohen J. (10 Feb 1996). Grand rounds - Hammersmith Hospital - Cerebral Whipple's disease. BRIT MED J. 312:371-373.
  • Spence SA; Hirsch SR; Liddle PF; Meehan J; Brooks DJ; Grasby PM. (Feb 1996). Willed movement in schizophrenia: A PET study. SCHIZOPHR RES. 18:XIIE7-XIIE7.
  • Brooks DJ. (1996). Basal ganglia function during normal and parkinsonian movement. PET activation studies. Adv Neurol. 69:433-441.
  • Lammertsma AA; Bench CJ; Hume SP; Osman S; Gunn K; Brooks DJ; Frackowiak RS. (Jan 1996). Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab. 16:42-52. DOI.
  • Brooks DJ. (1996). Functional imaging techniques in the diagnosis of non-Alzheimer dementias. J Neural Transm Suppl. 47:155-167.
  • Morrish PK; Sawle GV; Brooks DJ. (1996). The rate of progression of Parkinson's disease. A longitudinal [18F]DOPA PET study. Adv Neurol. 69:427-431.
  • Opacka-Juffry J; Ashworth S; Hume SP; Martin D; Brooks DJ; Blunt SB. (29 Dec 1995). GDNF protects against 6-OHDA nigrostriatal lesion: in vivo study with microdialysis and PET. Neuroreport. 7:348-352.
  • Morrish PK; Sawle GV; Brooks DJ. (Dec 1995). Clinical and [18F] dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry. 59:597-600.
  • Rinne JO; Burn DJ; Mathias CJ; Quinn NP; Marsden CD; Brooks DJ. (Dec 1995). Olivopontocerebellar atrophy - Reply. ANN NEUROL. 38:965-966.
  • O'Sullivan EP; Jenkins IH; Henderson L; Kennard C; Brooks DJ. (13 Nov 1995). The functional anatomy of remembered saccades: a PET study. Neuroreport. 6:2141-2144.
  • Haaxma R; vanBoxtel A; Brouwer WH; Goeken LNH; vanderGon JJD; Colebatch JG; Martin A; Brooks DJ; et alNoth J; Marsden CD. (Nov 1995). Motor function in a patient with bilateral lesions of the globus pallidus. MOVEMENT DISORD. 10:761-777.
  • TORRES EM; FRICKER RA; HUME SP; MYERS R; OPACKAJUFFRY J; ASHWORTH S; BROOKS DJ; DUNNETT SB. (23 Oct 1995). ASSESSMENT OF STRIATAL GRAFT VIABILITY IN THE RAT IN-VIVO USING A SMALL-DIAMETER PET SCANNER. NEUROREPORT. 6:2017-2021.
  • Hume SP; Opacka-Juffry J; Myers R; Ahier RG; Ashworth S; Brooks DJ; Lammertsma AA. (Sep 1995). Effect of L-dopa and 6-hydroxydopamine lesioning on [11C]raclopride binding in rat striatum, quantified using PET. Synapse. 21:45-53. DOI.
  • JAHANSHAHI M; JENKINS H; BROWN RG; MARSDEN CD; PASSINGHAM RE; BROOKS DJ. (Aug 1995). SELF-INITIATED VERSUS EXTERNALLY TRIGGERED MOVEMENTS .1. AN INVESTIGATION USING MEASUREMENT OF REGIONAL CEREBRAL BLOOD-FLOW WITH PET AND MOVEMENT-RELATED POTENTIALS IN NORMAL AND PARKINSONS-DISEASE SUBJECTS. BRAIN. 118:913-933.
  • Burn DJ; Rinne JO; Quinn NP; Lees AJ; Marsden CD; Brooks DJ. (Aug 1995). Striatal opioid receptor binding in Parkinson's disease, striatonigral degeneration and Steele-Richardson-Olszewski syndrome, A [11C]diprenorphine PET study. Brain. 118 ( Pt 4):951-958.
  • BURN DJ; RINNE JO; QUINN NP; LEES AJ; MARSDEN CD; BROOKS DJ. (Aug 1995). STRIATAL OPIOID RECEPTOR-BINDING IN PARKINSONS-DISEASE, STRIATONIGRAL DEGENERATION AND STEELE-RICHARDSON-OLSZEWSKI SYNDROME - A [C-11] DIPRENORPHINE PET STUDY. BRAIN. 118:951-958.
  • Prevett MC; Duncan JS; Jones T; Fish DR; Brooks DJ. (Jul 1995). Demonstration of thalamic activation during typical absence seizures using H2(15)O and PET. Neurology. 45:1396-1402.
  • Prevett MC; Lammertsma AA; Brooks DJ; Cunningham VJ; Fish DR; Duncan JS. (Jun 1995). Benzodiazepine-GABAA receptor binding during absence seizures. Epilepsia. 36:592-599.
  • Ceballos-Baumann AO; Passingham RE; Marsden CD; Brooks DJ. (Jun 1995). Motor reorganization in acquired hemidystonia. Ann Neurol. 37:746-757. DOI.
  • Turjanski N; Weeks R; Dolan R; Harding AE; Brooks DJ. (Jun 1995). Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain. 118 ( Pt 3):689-696.
  • TURJANSKI N; WEEKS R; DOLAN R; HARDING AE; BROOKS DJ. (Jun 1995). STRIATAL D-1 AND D-2 RECEPTOR-BINDING IN PATIENTS WITH HUNTINGTONS-DISEASE AND OTHER CHOREAS - A PET STUDY. BRAIN. 118:689-696.
  • Opacka-Juffry J; Brooks DJ. (May 1995). L-dihydroxyphenylalanine and its decarboxylase: new ideas on their neuroregulatory roles. Mov Disord. 10:241-249. DOI.
  • Rinne JO; Burn DJ; Mathias CJ; Quinn NP; Marsden CD; Brooks DJ. (May 1995). Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy. Ann Neurol. 37:568-573. DOI.
  • Playford ED; Britton TC; Thompson PD; Brooks DJ; Findley LJ; Marsden CD. (Apr 1995). Exacerbation of postural tremor with emergence of parkinsonism after treatment with neuroleptic drugs. J Neurol Neurosurg Psychiatry. 58:487-489.
  • Wills AJ; Jenkins IH; Thompson PD; Findley LJ; Brooks DJ. (Mar 1995). A positron emission tomography study of cerebral activation associated with essential and writing tremor. Arch Neurol. 52:299-305.
  • Ceballos-Baumann AO; Passingham RE; Warner T; Playford ED; Marsden CD; Brooks DJ. (Mar 1995). Overactive prefrontal and underactive motor cortical areas in idiopathic dystonia. Ann Neurol. 37:363-372. DOI.
  • Prevett MC; Lammertsma AA; Brooks DJ; Bartenstein PA; Patsalos PN; Fish DR; Duncan JS. (Feb 1995). Benzodiazepine-GABAA receptors in idiopathic generalized epilepsy measured with [11C]flumazenil and positron emission tomography. Epilepsia. 36:113-121.
  • Brooks DJ. (Feb 1995). Parkinson's disease--a single clinical entity?. QJM. 88:81-91.
  • MENZA MA; MARK MH; BURN DJ; BROOKS DJ. (1995). PERSONALITY-CORRELATES OF [F-18] DOPA STRIATAL UPTAKE - RESULTS OF POSITRON-EMISSION TOMOGRAPHY IN PARKINSONS-DISEASE. J NEUROPSYCH CLIN N. 7:176-179.
  • Piccini P; Turjanski N; Brooks DJ. (1995). PET studies of the striatal dopaminergic system in Parkinson's disease (PD). JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT. 123-131.
  • Brooks DJ; Torjanski N; Burn DJ. (1995). Ropinirole in the symptomatic treatment of Parkinson's disease. JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT. 231-238.
  • JAHANSHAHI M; JENKINS H; BROWN RG; MARSDEN C; BROOKS DJ; PASSINGHAM RE. (1995). SELF-INITIATED VS EXTERNALLY-TRIGGERED ACTIONS - THE EFFECTS OF STIMULUS PREDICTABILITY STUDIED WITH POSITRON EMISSION TOMOGRAPHY. J PSYCHOPHYSIOL. 9:177-178.
  • Brooks DJ. (Jan 1995). The role of the basal ganglia in motor control: contributions from PET. J Neurol Sci. 128:1-13.
  • Kew JJ; Ridding MC; Rothwell JC; Passingham RE; Leigh PN; Sooriakumaran S; Frackowiak RS; Brooks DJ. (Nov 1994). Reorganization of cortical blood flow and transcranial magnetic stimulation maps in human subjects after upper limb amputation. J Neurophysiol. 72:2517-2524.
  • ANDERSON TJ; JENKINS IH; BROOKS DJ; HAWKEN MB; FRACKOWIAK RSJ; KENNARD C. (Oct 1994). CORTICAL CONTROL OF SACCADES AND FIXATION IN MAN - A PET STUDY. BRAIN. 117:1073-1084.
  • Anderson TJ; Jenkins IH; Brooks DJ; Hawken MB; Frackowiak RS; Kennard C. (Oct 1994). Cortical control of saccades and fixation in man. A PET study. Brain. 117 ( Pt 5):1073-1084.
  • Wills AJ; Jenkins IH; Thompson PD; Findley LJ; Brooks DJ. (Oct 1994). Red nuclear and cerebellar but no olivary activation associated with essential tremor: a positron emission tomographic study. Ann Neurol. 36:636-642. DOI.
  • CEBALLOSBAUMANN AO; OBESO JA; VITEK JL; DELONG MR; BAKAY R; LINAZASORO G; BROOKS DJ. (17 Sep 1994). RESTORATION OF THALAMOCORTICAL ACTIVITY AFTER POSTEROVENTRAL PALLIDOTOMY IN PARKINSONS-DISEASE. LANCET. 344:814-814.
  • Prevett MC; Cunningham VJ; Brooks DJ; Fish DR; Duncan JS. (Sep 1994). Opiate receptors in idiopathic generalised epilepsy measured with [11C]diprenorphine and positron emission tomography. Epilepsy Res. 19:71-77.
  • BRYANT DJ; WEEKS RA; MARCUS CD; SARGENTONI J; TAYLORROBINSON S; BROOKS DJ. (16 Jul 1994). GLUTAMATE IN HUNTINGTONS-DISEASE - REPLY. LANCET. 344:189-190.
  • SAWLE GV; BURN DJ; MORRISH PK; LAMMERTSMA AA; SNOW BJ; LUTHRA S; OSMAN S; BROOKS DJ. (Jul 1994). THE EFFECT OF ENTACAPONE (OR-611) ON BRAIN [F-18] 6-L-FLUORODOPA METABOLISM - IMPLICATIONS FOR LEVODOPA THERAPY OF PARKINSONS-DISEASE. NEUROLOGY. 44:1292-1297.
  • Kew JJ; Brooks DJ; Passingham RE; Rothwell JC; Frackowiak RS; Leigh PN. (Jun 1994). Cortical function in progressive lower motor neuron disorders and amyotrophic lateral sclerosis: a comparative PET study. Neurology. 44:1101-1110.
  • Jenkins IH; Brooks DJ; Nixon PD; Frackowiak RS; Passingham RE. (Jun 1994). Motor sequence learning: a study with positron emission tomography. J Neurosci. 14:3775-3790.
  • Turjanski N; Sawle GV; Playford ED; Weeks R; Lammerstma AA; Lees AJ; Brooks DJ. (Jun 1994). PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome. J Neurol Neurosurg Psychiatry. 57:688-692.
  • TAYLORROBINSON SD; WEEKS RA; SARGENTONI J; MARCUS CD; BRYANT DJ; HARDING AE; BROOKS DJ. (7 May 1994). EVIDENCE FOR GLUTAMATE EXCITOTOXICITY IN HUNTINGTONS-DISEASE WITH PROTON MAGNETIC-RESONANCE SPECTROSCOPY. LANCET. 343:1170-1170.
  • WEEKS RA; LEES AJ; BROOKS DJ. (30 Apr 1994). TOURETTES-SYNDROME AND THE OPIOID SYSTEM. LANCET. 343:1107-1108.
  • CHAUDHURI KR; EDWARDS R; SAWLE GV; BROOKS DJ; FRACKOWIAK RSJ. (Mar 1994). CARPOPEDAL SPASM AS PRESENTING FEATURE OF ADULT MOYAMOYA DISEASE. CEREBROVASC DIS. 4:106-107.
  • Burn DJ; Sawle GV; Brooks DJ. (Mar 1994). Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatry. 57:278-284.
  • DEXTER DT; BROOKS DJ; HARDING AE; BURN DJ; MULLER DPR; GOSSSAMPSON MA; JENNER PG; MARSDEN CD. (Mar 1994). NIGROSTRIATAL FUNCTION IN VITAMIN-E-DEFICIENCY - CLINICAL, EXPERIMENTAL, AND POSITRON EMISSION TOMOGRAPHIC STUDIES. ANN NEUROL. 35:298-303.
  • Sawle GV; Playford ED; Burn DJ; Cunningham VJ; Brooks DJ. (Mar 1994). Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data. Arch Neurol. 51:237-243.
  • Brooks DJ. (1994). PET studies in progressive supranuclear palsy. J Neural Transm Suppl. 42:119-134.
  • Weeks RA; Brooks DJ. (1994). Positron emission tomography and central neurotransmitter systems in movement disorders. Fundam Clin Pharmacol. 8:503-517.
  • BLUNT SB; BROOKS DJ; KENNARD C. (Jan 1994). STEROID-RESPONSIVE CHOREA IN CHILDHOOD FOLLOWING CARDIAC TRANSPLANTATION. MOVEMENT DISORD. 9:112-114.
  • QUINN; BROOKS DJ; BAAS; OERTEL WH; SAGAR; GUTTMAN; BLANCHETTE. (Dec 1993). IMAGING IN EARLY AND DIFFERENTIAL-DIAGNOSIS OF PD - DISCUSSION. NEUROLOGY. 43:21-22.
  • Bartenstein PA; Duncan JS; Prevett MC; Cunningham VJ; Fish DR; Jones AK; Luthra SK; Sawle GV; et alBrooks DJ. (Dec 1993). Investigation of the opioid system in absence seizures with positron emission tomography. J Neurol Neurosurg Psychiatry. 56:1295-1302.
  • Brooks DJ. (Dec 1993). PET studies on the early and differential diagnosis of Parkinson's disease. Neurology. 43:S6-16.
  • Kew JJ; Goldstein LH; Leigh PN; Abrahams S; Cosgrave N; Passingham RE; Frackowiak RS; Brooks DJ. (Dec 1993). The relationship between abnormalities of cognitive function and cerebral activation in amyotrophic lateral sclerosis. A neuropsychological and positron emission tomography study. Brain. 116 ( Pt 6):1399-1423.
  • KEW JJM; GOLDSTEIN LH; LEIGH PN; ABRAHAMS S; COSGRAVE N; PASSINGHAM RE; FRACKOWIAK RSJ; BROOKS DJ. (Dec 1993). THE RELATIONSHIP BETWEEN ABNORMALITIES OF COGNITIVE FUNCTION AND CEREBRAL ACTIVATION IN AMYOTROPHIC-LATERAL-SCLEROSIS - A NEUROPSYCHOLOGICAL AND POSITRON EMISSION TOMOGRAPHY STUDY. BRAIN. 116:1399-1423.
  • CHAUDHURI KR; EDWARDS R; SCOTT J; BROOKS DJ; REES A; PUSEY CD. (2 Oct 1993). GRAND ROUNDS - HAMMERSMITH-HOSPITAL - ADULT MOYAMOYA DISEASE. BRIT MED J. 307:852-854.
  • Playford ED; Fletcher NA; Sawle GV; Marsden CD; Brooks DJ. (Oct 1993). Striatal [18F]dopa uptake in familial idiopathic dystonia. Brain. 116 ( Pt 5):1191-1199.
  • PLAYFORD ED; FLETCHER NA; SAWLE GV; MARSDEN CD; BROOKS DJ. (Oct 1993). STRIATAL [F-18] DOPA UPTAKE IN FAMILIAL IDIOPATHIC DYSTONIA. BRAIN. 116:1191-1199.
  • Sawle GV; Lees AJ; Hymas NF; Brooks DJ; Frackowiak RS. (Sep 1993). The metabolic effects of limbic leucotomy in Gilles de la Tourette syndrome. J Neurol Neurosurg Psychiatry. 56:1016-1019.
  • SAWLE GV; PLAYFORD ED; BROOKS DJ; QUINN N; FRACKOWIAK RSJ. (Aug 1993). ASYMMETRICAL PRESYNAPTIC AND POSTSYNAPTIC CHANGES IN THE STRIATAL DOPAMINE PROJECTION IN DOPA NAIVE PARKINSONISM - DIAGNOSTIC IMPLICATIONS OF THE D2 RECEPTOR STATUS. BRAIN. 116:853-867.
  • Sawle GV; Playford ED; Brooks DJ; Quinn N; Frackowiak RS. (Aug 1993). Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status. Brain. 116 ( Pt 4):853-867.
  • Turjanski N; Bhatia K; Burn DJ; Sawle GV; Marsden CD; Brooks DJ. (Aug 1993). Comparison of striatal 18F-dopa uptake in adult-onset dystonia-parkinsonism, Parkinson's disease, and dopa-responsive dystonia. Neurology. 43:1563-1568.
  • Jenkins IH; Bain PG; Colebatch JG; Thompson PD; Findley LJ; Frackowiak RS; Marsden CD; Brooks DJ. (Jul 1993). A positron emission tomography study of essential tremor: evidence for overactivity of cerebellar connections. Ann Neurol. 34:82-90. DOI.
  • Kew JJ; Leigh PN; Playford ED; Passingham RE; Goldstein LH; Frackowiak RS; Brooks DJ. (Jun 1993). Cortical function in amyotrophic lateral sclerosis. A positron emission tomography study. Brain. 116 ( Pt 3):655-680.
  • KEW JJM; LEIGH PN; PLAYFORD ED; PASSINGHAM RE; GOLDSTEIN LH; FRACKOWIAK RSJ; BROOKS DJ. (Jun 1993). CORTICAL FUNCTION IN AMYOTROPHIC-LATERAL-SCLEROSIS - A POSITRON EMISSION TOMOGRAPHY STUDY. BRAIN. 116:655-680.
  • BARTENSTEIN P; PREVETT MC; FISH DR; LUTHRA SK; BROOKS DJ; DUNCAN JS. (May 1993). DIFFERENT KINETICS OF C-11 DIPRENORPHINE IN PATIENTS WITH ABSENCE-EPILEPSY WITH AND WITHOUT PROVOCATION OF SEIZURES. J NUCL MED. 34:P57-P58.
  • Brooks DJ. (Mar 1993). Functional imaging in relation to parkinsonian syndromes. J Neurol Sci. 115:1-17.
  • Burn DJ; Brooks DJ. (Mar 1993). Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study. Neurology. 43:552-556.
  • Playford ED; Jenkins IH; Passingham RE; Frackowiak RS; Brooks DJ. (1993). Impaired activation of frontal areas during movement in Parkinson's disease: a PET study. Adv Neurol. 60:506-510.
  • Jenkins IH; Fernandez W; Playford ED; Lees AJ; Frackowiak RS; Passingham RE; Brooks DJ. (Dec 1992). Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann Neurol. 32:749-757. DOI.
  • Sawle GV; Wroe SJ; Lees AJ; Brooks DJ; Frackowiak RS. (Nov 1992). The identification of presymptomatic parkinsonism: clinical and [18F]dopa positron emission tomography studies in an Irish kindred. Ann Neurol. 32:609-617. DOI.
  • Burn DJ; Mark MH; Playford ED; Maraganore DM; Zimmerman TR; Duvoisin RC; Harding AE; Marsden CD; et alBrooks DJ. (Oct 1992). Parkinson's disease in twins studied with 18F-dopa and positron emission tomography. Neurology. 42:1894-1900.
  • Hume SP; Myers R; Bloomfield PM; Opacka-Juffry J; Cremer JE; Ahier RG; Luthra SK; Brooks DJ; et alLammertsma AA. (Sep 1992). Quantitation of carbon-11-labeled raclopride in rat striatum using positron emission tomography. Synapse. 12:47-54. DOI.
  • Playford ED; Jenkins IH; Passingham RE; Nutt J; Frackowiak RS; Brooks DJ. (Aug 1992). Impaired mesial frontal and putamen activation in Parkinson's disease: a positron emission tomography study. Ann Neurol. 32:151-161. DOI.
  • Brooks DJ; Playford ED; Ibanez V; Sawle GV; Thompson PD; Findley LJ; Marsden CD. (Aug 1992). Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology. 42:1554-1560.
  • SALMON E; BROOKS DJ. (Feb 1992). INVIVO DISTRIBUTION OF CATECHOLAMINE REUPTAKE SITES IN HUMAN BRAIN GIVES CLUES TO THE PHYSIOPATHOLOGY OF MPTP-INDUCED PARKINSONISM. J NEUROL NEUROSUR PS. 55:167-167.
  • Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; et alBannister R; Frackowiak RS. (Feb 1992). Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol. 31:184-192. DOI.
  • SAWLE GV; BLOOMFIELD PM; BJORKLUND A; BROOKS DJ; BRUNDIN P; LEENDERS KL; LINDVALL O; MARSDEN CD; et alREHNCRONA S; WIDNER H; FRACKOWIAK RSJ. (Feb 1992). TRANSPLANTATION OF FETAL DOPAMINE NEURONS IN PARKINSONS-DISEASE - PET [F-18] 6-L-FLUORODOPA STUDIES IN 2 PATIENTS WITH PUTAMINAL IMPLANTS. ANN NEUROL. 31:166-173.
  • Playford ED; Brooks DJ. (1992). In vivo and in vitro studies of the dopaminergic system in movement disorders. Cerebrovasc Brain Metab Rev. 4:144-171.
  • Brooks DJ; Turjanski N; Sawle GV; Playford ED; Lees AJ. (1992). PET studies on the integrity of the pre and postsynaptic dopaminergic system in Tourette syndrome. Adv Neurol. 58:227-231.
  • JENKINS IH; PASSINGHAM RE; NIXON PD; FRACKOWIAK RSJ; BROOKS DJ. (1992). THE LEARNING OF MOTOR SEQUENCES - A PET STUDY. EUR J NEUROSCI. 174-174.
  • JOHNSTON SRD; BURN DJ; BROOKS DJ. (Nov 1991). PERIPHERAL NEUROPATHY ASSOCIATED WITH LITHIUM TOXICITY. J NEUROL NEUROSUR PS. 54:1019-1020.
  • HUME SP; MYERS R; TURTON DR; BLOOMFIELD PM; BROOKS DJ; LAMMERTSMA AA. (Sep 1991). QUANTITATION OF C-11 LABELED RACLOPRIDE IN RAT STRIATUM USING PET. J NUCL MED. 32:1838-1838.
  • Brooks DJ. (Aug 1991). Detection of preclinical Parkinson's disease with PET. Geriatrics. 46 Suppl 1:25-30.
  • Brooks DJ; Ibanez V; Playford ED; Sawle GV; Leigh PN; Kocen RS; Harding AE; Marsden CD. (Aug 1991). Presynaptic and postsynaptic striatal dopaminergic function in neuroacanthocytosis: a positron emission tomographic study. Ann Neurol. 30:166-171. DOI.
  • Sawle GV; Leenders KL; Brooks DJ; Harwood G; Lees AJ; Frackowiak RS; Marsden CD. (Jul 1991). Dopa-responsive dystonia: [18F]dopa positron emission tomography. Ann Neurol. 30:24-30. DOI.
  • BROOKS DJ. (Jun 1991). THE DIAGNOSIS OF MULTIPLE SYSTEM ATROPHY - REPLY. ANN NEUROL. 29:690-690.
  • Brooks DJ. (May 1991). Detection of preclinical Parkinson's disease with PET. Neurology. 41:24-27.
  • SAWLE GV; BROOKS DJ; MARSDEN CD; FRACKOWIAK RSJ. (Feb 1991). CORTICOBASAL DEGENERATION - A UNIQUE PATTERN OF REGIONAL CORTICAL OXYGEN HYPOMETABOLISM AND STRIATAL FLUORODOPA UPTAKE DEMONSTRATED BY POSITRON EMISSION TOMOGRAPHY. BRAIN. 114:541-556.
  • Sawle GV; Brooks DJ; Marsden CD; Frackowiak RS. (Feb 1991). Corticobasal degeneration. A unique pattern of regional cortical oxygen hypometabolism and striatal fluorodopa uptake demonstrated by positron emission tomography. Brain. 114 ( Pt 1B):541-556.
  • BROOKS DJ. (Jan 1991). PET - ITS CLINICAL ROLE IN NEUROLOGY. J NEUROL NEUROSUR PS. 54:1-5.
  • Brooks DJ. (1991). The clinical role of PET in cerebrovascular disease. Neurosurg Rev. 14:91-96.
  • Chollet F; DiPiero V; Wise RJ; Brooks DJ; Dolan RJ; Frackowiak RS. (Jan 1991). The functional anatomy of motor recovery after stroke in humans: a study with positron emission tomography. Ann Neurol. 29:63-71. DOI.
  • Sawle GV; Colebatch JG; Shah A; Brooks DJ; Marsden CD; Frackowiak RS. (Dec 1990). Striatal function in normal aging: implications for Parkinson's disease. Ann Neurol. 28:799-804. DOI.
  • Leenders KL; Salmon EP; Tyrrell P; Perani D; Brooks DJ; Sager H; Jones T; Marsden CD; et alFrackowiak RS. (Dec 1990). The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol. 47:1290-1298.
  • Colebatch JG; Findley LJ; Frackowiak RS; Marsden CD; Brooks DJ. (27 Oct 1990). Preliminary report: activation of the cerebellum in essential tremor. Lancet. 336:1028-1030.
  • Brooks DJ; Ibanez V; Sawle GV; Quinn N; Lees AJ; Mathias CJ; Bannister R; Marsden CD; et alFrackowiak RS. (Oct 1990). Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol. 28:547-555. DOI.
  • Brooks DJ; Salmon EP; Mathias CJ; Quinn N; Leenders KL; Bannister R; Marsden CD; Frackowiak RS. (Oct 1990). The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain. 113 ( Pt 5):1539-1552.
  • BROOKS DJ; SALMON EP; MATHIAS CJ; QUINN N; LEENDERS KL; BANNISTER R; MARSDEN CD; FRACKOWIAK RSJ. (Oct 1990). THE RELATIONSHIP BETWEEN LOCOMOTOR DISABILITY, AUTONOMIC DYSFUNCTION, AND THE INTEGRITY OF THE STRIATAL DOPAMINERGIC SYSTEM IN PATIENTS WITH MULTIPLE SYSTEM ATROPHY, PURE AUTONOMIC FAILURE, AND PARKINSONS-DISEASE, STUDIED WITH PET. BRAIN. 113:1539-1552.
  • Salmon E; Brooks DJ; Leenders KL; Turton DR; Hume SP; Cremer JE; Jones T; Frackowiak RS. (May 1990). A two-compartment description and kinetic procedure for measuring regional cerebral [11C]nomifensine uptake using positron emission tomography. J Cereb Blood Flow Metab. 10:307-316. DOI.
  • LEENDERS KL; PERANI D; LAMMERTSMA AA; HEATHER JD; BUCKINGHAM P; HEALY MJR; GIBBS JM; WISE RJS; et alHATAZAWA J; HEROLD S; BEANEY RP; BROOKS DJ; SPINKS T; RHODES C; FRACKOWIAK RSJ; JONES T. (Feb 1990). CEREBRAL BLOOD-FLOW, BLOOD-VOLUME AND OXYGEN UTILIZATION - NORMAL VALUES AND EFFECT OF AGE. BRAIN. 113:27-47.
  • SAWLE GV; BROOKS DJ. (1990). POSITRON EMISSION TOMOGRAPHY STUDIES OF NEUROTRANSMITTER SYSTEMS. J NEUROL. 237:451-456.
  • BEANEY RP; BROOKS DJ; JONES T. (Jan 1990). THE LATE EFFECTS OF CEREBRAL IRRADIATION. BRIT J CANCER. 61:165-166.
  • Brooks DJ. (Dec 1989). Positron emission tomographic studies of the subcortical degenerations and dystonia. Semin Neurol. 9:351-359. DOI.
  • Godlee FN; Brooks DJ; Impallomeni M. (Nov 1989). Dyskinesia in the elderly presenting as respiratory disorder. Postgrad Med J. 65:830-831.
  • Brooks DJ; Frackowiak RS. (Jun 1989). PET and movement disorders. J Neurol Neurosurg Psychiatry. Suppl:68-77.
  • BROOKS DJ; FRACKOWIAK RSJ. (Jun 1989). PET AND MOVEMENT-DISORDERS. J NEUROL NEUROSUR PS. 68-77.
  • BROOKS DJ; REDMOND S; BANNISTER R; MATTHIAS C; SYMON L. (Oct 1988). THE EFFECT OF EPHEDRINE ON CEREBRAL BLOOD-FLOW AND MIDDLE CEREBRAL-ARTERY VELOCITY IN PATIENTS WITH ORTHOSTATIC HYPOTENSION. J NEUROL NEUROSUR PS. 51:1359-1359.
  • FISH DR; BROOKS DJ; YOUNG IR; BYDDER GM. (Oct 1988). USE OF MAGNETIC-RESONANCE IMAGING TO IDENTIFY CHANGES IN CEREBRAL BLOOD-FLOW IN EPILEPSIA PARTIALIS CONTINUA. MAGNET RESON MED. 8:238-240.
  • BEANEY RP; LEENDERS KL; BROOKS DJ. (7 Mar 1987). EFFECTS OF DEXAMETHASONE IN BRAIN-TUMOR PATIENTS. LANCET. 1:571-572.
  • BROOKS DJ; CARR DH; LEGG NJ. (Mar 1987). THE ROLE OF DELAYED COMPUTED TOMOGRAPHIC SCANNING USING HIGH-DOSES OF CONTRAST MATERIAL IN DETECTING CEREBRAL DEMYELINATION IN PATIENTS WITH MULTIPLE-SCLEROSIS IN RELAPSE AND REMISSION. BRIT J RADIOL. 60:295-297.
  • Beaney RP; Gibbs JS; Brooks DJ; McKenzie CG; Joplin GF; Jones T. (1987). Absence of irradiation induced ischaemic temporal lobe damage in patients with pituitary tumours. J Neurooncol. 5:129-137.
  • LAMMERTSMA AA; BROOKS DJ; FRACKOWIAK RSJ; BEANEY RP; HEROLD S; HEATHER JD; PALMER AJ; JONES T. (1987). MEASUREMENT OF GLUCOSE-UTILIZATION WITH [F-18] 2-FLUORO-2-DEOXY-D-GLUCOSE - A COMPARISON OF DIFFERENT ANALYTICAL METHODS. J CEREBR BLOOD F MET. 7:161-172.
  • SPEIRS CJ; NAVEY FL; BROOKS DJ; IMPALLOMENI MG. (8 Nov 1986). OPISTHOTONOS AND BENZODIAZEPINE WITHDRAWAL IN THE ELDERLY. LANCET. 2:1101-1101.
  • BROOKS DJ; BEANEY RP; POWELL M; LEENDERS KL; CROCKARD HA; THOMAS DGT; MARSHALL J; JONES T. (Aug 1986). STUDIES ON CEREBRAL OXYGEN-METABOLISM, BLOOD-FLOW, AND BLOOD-VOLUME, IN PATIENTS WITH HYDROCEPHALUS BEFORE AND AFTER SURGICAL DECOMPRESSION, USING POSITRON EMISSION TOMOGRAPHY. BRAIN. 109:613-628.
  • BROOKS DJ; BEANEY RP; LAMMERTSMA AA; TURTON DR; MARSHALL J; THOMAS DGT; JONES T. (May 1986). STUDIES ON REGIONAL CEREBRAL HEMATOCRIT AND BLOOD-FLOW IN PATIENTS WITH CEREBRAL-TUMORS USING POSITRON EMISSION TOMOGRAPHY. MICROVASC RES. 31:267-276.
  • BROOKS DJ; FRACKOWIAK RSJ; LAMMERTSMA AA; HEROLD S; LEENDERS KL; SELWYN AP; TURTON DR; BRADY F; et alJONES T. (Apr 1986). A COMPARISON BETWEEN REGIONAL CEREBRAL BLOOD-FLOW MEASUREMENTS OBTAINED IN HUMAN-SUBJECTS USING C-11 METHYLALBUMIN MICROSPHERES, THE C15O2 STEADY-STATE METHOD, AND POSITRON EMISSION TOMOGRAPHY. ACTA NEUROL SCAND. 73:415-422.
  • BROOKS DJ; BEANEY RP; THOMAS DGT. (Mar 1986). THE ROLE OF POSITRON EMISSION TOMOGRAPHY IN THE STUDY OF CEREBRAL-TUMORS. SEMIN ONCOL. 13:83-93.
  • BROOKS DJ; BEANEY RP; LAMMERTSMA AA; HEROLD S; TURTON DR; LUTHRA SK; FRACKOWIAK RSJ; THOMAS DGT; et alMARSHALL J; JONES T. (1986). GLUCOSE-TRANSPORT ACROSS THE BLOOD-BRAIN-BARRIER IN NORMAL HUMAN-SUBJECTS AND PATIENTS WITH CEREBRAL-TUMORS STUDIED USING [C-11] 3-O-METHYL-D-GLUCOSE AND POSITRON EMISSION TOMOGRAPHY. J CEREBR BLOOD F MET. 6:230-239.
  • BROOKS DJ; GIBBS JSR; SHARP P; HEROLD S; TURTON DR; LUTHRA SK; KOHNER EM; BLOOM SR; et alJONES T. (1986). REGIONAL CEREBRAL GLUCOSE-TRANSPORT IN INSULIN-DEPENDENT DIABETIC-PATIENTS STUDIED USING [C-11] 3-O-METHYL-D-GLUCOSE AND POSITRON EMISSION TOMOGRAPHY. J CEREBR BLOOD F MET. 6:240-244.
  • BROOKS DJ; BEANEY RP; THOMAS DGT; MARSHALL J; JONES T. (1986). STUDIES ON REGIONAL CEREBRAL PH IN PATIENTS WITH CEREBRAL-TUMORS USING CONTINUOUS INHALATION OF (CO2)-C-11 AND POSITRON EMISSION TOMOGRAPHY. J CEREBR BLOOD F MET. 6:529-535.
  • BEANEY RP; BROOKS DJ; LEENDERS KL; THOMAS DGT; JONES T; HALNAN KE. (1985). BLOOD-FLOW AND OXYGEN UTILIZATION IN THE CONTRALATERAL CEREBRAL-CORTEX OF PATIENTS WITH UNTREATED INTRACRANIAL TUMORS AS STUDIED BY POSITRON EMISSION TOMOGRAPHY, WITH OBSERVATIONS ON THE EFFECT OF DECOMPRESSIVE SURGERY. J NEUROL NEUROSUR PS. 48:310-319.
  • LEENDERS KL; BEANEY RP; BROOKS DJ; LAMMERTSMA AA; HEATHER JD; MCKENZIE CG. (1985). DEXAMETHASONE TREATMENT OF BRAIN-TUMOR PATIENTS - EFFECTS ON REGIONAL CEREBRAL BLOOD-FLOW, BLOOD-VOLUME, AND OXYGEN UTILIZATION. NEUROLOGY. 35:1610-1616.
  • BROOKS DJ; BEANEY RP; GIBBS JSR; LAMMERTSMA AA; HEROLD S; TURTON DR; LUTHRA SK; THOMAS DGT; et alMARSHALL J; JONES T. (1985). GLUCOSE-TRANSPORT ACROSS THE BLOOD-BRAIN-BARRIER OF NORMAL SUBJECTS, DIABETIC-PATIENTS, AND PATIENTS WITH BRAIN-TUMORS STUDIED USING C-11-3-0-METHYL-D-GLUCOSE AND PET. ACTA NEUROL SCAND. 72:84-85.
  • THOMAS DGT; BROOKS DJ; BEANEY RP. (1985). POSITRON EMISSION TOMOGRAPHY IN BRAIN-TUMOR IMAGING. PROG EXP TUMOR RES. 29:50-56.
  • BROOKS DJ; BEANEY RP; LEENDERS KL; MARSHALL J; THOMAS DJ; JONES T. (1985). REGIONAL CEREBRAL OXYGEN UTILIZATION, BLOOD-FLOW, AND BLOOD-VOLUME IN BENIGN INTRACRANIAL HYPERTENSION STUDIED BY POSITRON EMISSION TOMOGRAPHY. NEUROLOGY. 35:1030-1034.
  • BEANEY RP; BROOKS DJ; JONES T; LAMMERTSMA AA; MARSHALL J; THOMAS DGT. (1985). STUDIES ON BLOOD-BRAIN BARRIER TRANSPORT IN HUMAN-SUBJECTS USING POSITRON EMISSION TOMOGRAPHY (PET). J PHYSIOL-LONDON. 360:P30-P30.
  • LAMMERTSMA AA; BROOKS DJ; FRACKOWIAK RSJ; HEATHER JD; JONES T. (1984). A METHOD TO QUANTITATE THE FRACTIONAL EXTRACTION OF RUBIDIUM-82 ACROSS THE BLOOD-BRAIN-BARRIER USING POSITRON EMISSION TOMOGRAPHY. J CEREBR BLOOD F MET. 4:523-534.
  • LAMMERTSMA AA; BROOKS DJ; BEANEY RP; TURTON DR; KENSETT MJ; HEATHER JD; MARSHALL J; JONES T. (1984). INVIVO MEASUREMENT OF REGIONAL CEREBRAL HEMATOCRIT USING POSITRON EMISSION TOMOGRAPHY. J CEREBR BLOOD F MET. 4:317-322.
  • BEANEY RP; BROOKS DJ; LEENDERS KL; LAMMERTSMA AA; JONES T; HALNAN KE. (1984). INVIVO MEASUREMENTS OF REGIONAL BLOOD-FLOW, BLOOD-VOLUME AND OXYGEN UTILIZATION IN HUMAN-TUMORS. INT J MICROCIRC. 3:565-565.
  • BROOKS DJ; LAMMERTSMA AA; BEANEY RP; LEENDERS KL; BUCKINGHAM PD; MARSHALL J; JONES T. (1984). MEASUREMENT OF REGIONAL CEREBRAL PH IN HUMAN-SUBJECTS USING CONTINUOUS INHALATION OF (CO2)-C-11 AND POSITRON EMISSION TOMOGRAPHY. J CEREBR BLOOD F MET. 4:458-465.
  • LEENDERS KL; HEROLD S; BROOKS DJ; PALMER AJ; TURTON D; FIRNAU G; GARNETT ES; NAHMIAS C; et alVEALL N. (1984). PRE-SYNAPTIC AND POST-SYNAPTIC DOPAMINERGIC SYSTEM IN HUMAN-BRAIN. LANCET. 2:110-111.
  • BROOKS DJ; BEANEY RP; LAMMERTSMA AA; LEENDERS KL; HORLOCK PL; KENSETT MJ; MARSHALL J; THOMAS DG; et alJONES T. (1984). QUANTITATIVE MEASUREMENT OF BLOOD-BRAIN-BARRIER PERMEABILITY USING RUBIDIUM-82 AND POSITRON EMISSION TOMOGRAPHY. J CEREBR BLOOD F MET. 4:535-545.
  • BROOKS DJ; LEENDERS KL; MARSHALL J; LEGG NJ; JONES T. (1984). REGIONAL CEREBRAL OXYGEN UTILIZATION, CEREBRAL BLOOD-FLOW, AND BLOOD-BRAIN-BARRIER INTEGRITY IN MULTIPLE-SCLEROSIS. J NEUROL NEUROSUR PS. 47:1053-1053.
  • BROOKS DJ; BEANEY RP; LEENDERS KL; MARSHALL J; LAMMERTSMA AA; JONES T. (1984). STUDIES ON REGIONAL BLOOD-BRAIN-BARRIER PERMEABILITY IN PATIENTS USING RB-82+, C-11-METHYL-ALBUMIN AND POSITRON EMISSION TOMOGRAPHY. CLIN SCI. 66:P68-P68.
  • BROOKS DJ; LEENDERS KL; HEAD G; MARSHALL J; LEGG NJ; JONES T. (1984). STUDIES ON REGIONAL CEREBRAL OXYGEN UTILIZATION AND COGNITIVE FUNCTION IN MULTIPLE-SCLEROSIS. J NEUROL NEUROSUR PS. 47:1182-1191.
  • LEENDERS KL; BEANEY RP; BROOKS DJ. (1984). THE EFFECTS OF DEXAMETHASONE ON REGIONAL CEREBRAL BLOOD-FLOW AND OXYGEN-METABOLISM IN BRAIN-TUMOR PATIENTS. CLIN SCI. 66:P17-P17.
  • BEANEY RP; BROOKS DJ; HALNAN KE; JONES T. (1984). THE MEASUREMENT OF REGIONAL TISSUE FUNCTION USING POSITRON EMISSION TOMOGRAPHY. BRIT J CANCER. 50:558-558.
  • Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E; LARGO study group. (12 Mar 2005). Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 365:947-954. DOI.

Chapters in books

  • Brooks DJ. Movement disorders: functional imaging. In Parkinson's disease and movement disorders. 4th:95-110. (2002).
  • Brooks DJ; Andrews T. Imaging Huntington's disease. In Huntington's disease. 3rd:95-110. (2002).

Conferences

  • Watson BJ; Taylor LG; Reid A; Wilson SJ; Stokes PR; Brooks DJ; Bose SK; Turkheimer F; et alLingford-Hughes AR; Nutt DJ. Investigating the effect of expectation on striatal dopamine release in heroin addicts: an C-11-raclopride PET study. 21:S320-S320. (Sep 2011).
  • Lingford-Hughes A; Myers J; Wilson S; Stokes P; Taylor L; Watson B; Kalk N; Besson M; et alFeeney A; Rosso L; Turkheimer F; Cunningham VJ; Pike VW; Brooks DJ; Marshall EJ; Kerwin RW; Nutt DJ. THE GABA-BENZODIAZEPINE RECEPTOR, ITS SUBTYPES AND ALCOHOL MISUSE: INSIGHTS FROM IMAGING AND PHARMACOLOGICAL CHALLENGE STUDIES. 25:A79-A79. (Aug 2011).
  • McGinnity CJ; Hammers A; Barros DAR; Gousias IS; Luthra SK; Jones PA; Trigg W; Brooks DJ; et alKoepp MJ; Duncan JS. [F-18]GE-179 PET DEMONSTRATES INCREASED NMDA RECEPTOR AVAILABILITY IN PATIENTS WITH REFRACTORY EPILEPSY AND FREQUENT INTERICTAL EPILEPTIFORM DISCHARGES (IEDS). 52:19-19. (Aug 2011).
  • Barros DAR; Heckemann RA; Keihaninejad S; McGinnity CJ; Gousias IS; Duncan JS; Koepp MJ; Brooks DJ; et alHammers A. TOWARD INVESTIGATING THE CAUSES OF MEMORY DIFFICULTIES IN TEMPORAL LOBE EPILEPSY: A STUDY USING THE NOVEL ALPHA5 GABA(A) RECEPTOR PET LIGAND [C-11]RO15 4513. 51:136-136. (Jun 2010).
  • Bose SK; Ramlackhansingh AF; Ahmed I; Pavese N; Brooks DJ; Turkheimer FE. Quantitation of adenosine A2A receptors availability in Parkinson's Disease patients with and without dyskinesias with [11C]SCH442416 PET using spectral analysis. 52:S216-S217. (Aug 2010). DOI.
  • McGinnity CJ; Shidahara M; Keihaninejad S; Barros DAR; Gousias IS; Heckemann RA; Brooks DJ; Koepp MJ; et alTurkheimer FE; Hammers A. Correction of [11C]diprenorphine PET data for the partial-volume effect: Quantification of opioid receptor binding following spontaneous epileptic seizures. 52:S209-S209. (Aug 2010). DOI.
  • Myers JFM; Rosso L; Kalk NJ; Watson BJ; Wilson S; Brooks DJ; Nutt DJ; Turkheimer FE; et alLingford-Hughes AR. The effects of zolpidem on in vivo binding of [C11]-flumazenil and [C11]-Ro15-4513. 52:S191-S192. (Aug 2010). DOI.
  • Galazzo IB; Bose SK; Ramlackhansingh AF; Ahmed I; Pavese N; Rizzo G; Brooks DJ; Turkheimer FE; et alBertoldo A. Kinetic modeling of the adenosine A2A subtype receptor radioligand [11C]SCH442416 in humans. 52:S178-S178. (Aug 2010). DOI.
  • Owenius R; Thurfjell L; Buckley CJ; Vandenberghe R; Van Laere K; Salmon E; Law I; Waldemar G; et alBrooks DJ; Farrar G. Subject classification from [18F]flutemetamol data into categories of raised or low levels of beta-amyloid: Concordance between quantitative and visual assessment. 52:S144-S144. (Aug 2010). DOI.
  • Heurling K; Vandenberghe R; Owenius R; Thurfjell L; Buckley CJ; Brooks DJ. Pons as an alternative reference region in [18F]flutemetamol quantification of amyloidosis. 52:S137-S137. (Aug 2010). DOI.
  • Barros DAR; Heckemann RA; Rosso L; McGinnity CJ; Keihaninejad S; Gousias IS; Brooks DJ; Duncan JS; et alKoepp MJ; Turkheimer FE; Hammers A. Investigating the reproducibility of the novel Alpha-5 GABAA receptor PET ligand [11C]Ro15 4513. 52:S112-S112. (Aug 2010). DOI.
  • Brooks DJ. Movement disorders: PET. 285:S7-S8. (Oct 2009).
  • Brooks DJ. Advances in neuromaging Parkinson's disease. 256:S8-S8. (Jun 2009).
  • TURJANSKI N; WEEKS R; SAWLE GV; BROOKS DJ. PET studies of the dopaminergic and opioid function in dopa-responsive dystonic syndromes and Tourette's syndrome. 14:77-86. (1995).
  • Rakshi JS; Bailey DL; Ito K; Uema T; Morrish PK; Ashburner J; Friston KJ; Brooks DJ. Methodology for statistical parametric mapping of [F-18]fluorodopa uptake rate using three-dimensional PET. 117-123. (1998).
  • Brooks DJ. Imaging impulse control disorders with PET. 23:1340-1340. (15 Jul 2008).
  • Swingland JT; Edison P; Bose SK; Okello A; Brooks DJ; Turkheimer FE. Disentangling functional imaging end-points in Alzheimer's disease. 41:T117-T117. (2008). DOI.
  • Brooks DJ. Assessment of Parkinson's disease with imaging. 13:S268-S275. (2007).
  • Grover VP; Pavese N; Koh SB; Wylezinska M; McGuinness A; Saxby BK; Gerhard A; Forton DM; et alThomas HC; Brooks DJ; Taylor-Robinson SD. Evidence of neuroinflammation in patients with chronic hepatitis C: A cerebral positron emission tomography (PET) study. 43rd Annual Meeting of the European-Association-for-the-Study-of-the-Liver. 48:S275-S275. (Feb 2008).
  • Brooks DJ. Modification of L-DOPA metabolism: Benefits and problems. 34:S7-S7. (9 Jun 2008). DOI.
  • Laszlovszky I; Nemeth G; Meszaros GP; Kapas M; Brooks DJ; Pavese N; Szombathelyi Z. Positron emission tomography (PET) study with RGH-188 in healthy volunteers. 63:287S-287S. (1 Apr 2008).
  • Okello A; Edison P; Archer H; Walker Z; Fox N; Kennedy A; Rossor M; Brooks DJ. In vivo imaging of amyloid deposition and neuroinflammation in mild cognitive impairment with 11C-PIB and 11C-PK11195 pet. 79:341-341. (Mar 2008).
  • Pavese N; Khan NL; Wood NW; Quinn NP; Lees AJ; Brooks DJ; Piccini P. Nigrostriatal dysfunction in parkin linked parkinsonism and asymptomatic heterozygous carriers: A progressive study with 18-dopa pet. 79:341-341. (Mar 2008).
  • Hammers A; Panagoda P; Heckemann RA; Kelsch W; Turkheimer FE; Brooks DJ; Duncan JS; Koepp MJ. Quantification strategies for [11C]flumazenil pet in temporal lobe epilepsy: Do they matter?. 61st Annual Meeting of the American-Epilepsy-Society. 48:162-163. (Oct 2007).
  • Laszovszky I; Nemeth G; Meszaros GP; Kapas M; Brooks DJ; Pavese N; Szombathelyi Z. Dopamine 1321133 receptor occupancy of RGH-188, a D3/D2 antagonist/partial agonist antipsychotic, in healthy volunteers. 20th Congress of the European-College-of-Neuropsychopharmacology. 17:S455-S455. (Oct 2007).
  • Williams TM; Lingford-Hughes A; Davies SJC; Daglish MRC; Taylor LG; Hammers A; Brooks DJ; Grasby P; et alMyles JS; Nutt DJ. Increased opioid receptor binding in early abstinence from dependent opioid and alcohol use and relationship to craving. 17:S187-S188. (Oct 2007).
  • Gordin A; Brooks DJ. Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease. 254:37-48. (Aug 2007). DOI.
  • Rice CM; Whone AL; Marks DI; Butler SB; Brooks DJ; Scolding NJ. A safety and feasibility study of intravenous autologous bone marrow stem cells in multiple sclerosis. 78:1036-1036. (Sep 2007).
  • BROOKS DJ; TURJANSKI N; SAWLE GV; PLAYFORD ED; LEES AJ. PET STUDIES ON THE INTEGRITY OF THE PRESYNAPTIC AND POSTSYNAPTIC DOPAMINERGIC SYSTEM IN TOURETTE SYNDROME. 2ND INTERNATIONAL SCIENTIFIC SYMP ON TOURETTE SYNDROME. 58:227-231. (1992).
  • PLAYFORD ED; JENKINS IH; PASSINGHAM RE; FRACKOWIAK RSJ; BROOKS DJ. IMPAIRED ACTIVATION OF FRONTAL AREAS DURING MOVEMENT IN PARKINSONS-DISEASE - A PET STUDY. 10TH INTERNATIONAL SYMP ON PARKINSONS DISEASE. 60:506-510. (1993).
  • BROOKS DJ. PET STUDIES ON THE EARLY AND DIFFERENTIAL-DIAGNOSIS OF PARKINSONS-DISEASE. Symposium on Parkinsons Disease: Diagnosis and Therapy, as a Satellite to the 2nd International Congress of Movement Disorders. 43:6-16. (Dec 1993).
  • BROOKS DJ. PET STUDIES IN PROGRESSIVE SUPRANUCLEAR PALSY. Symposium on Advances in Progressive Supranuclear Palsy. 119-134. (1994).
  • ABRAHAMS S; GOLDSTEIN LH; LLOYD CM; BROOKS DJ; LEIGH PN. Cognitive deficits in non-demented amyotrophic lateral sclerosis patients: A neuropsychological investigation. 5th International Symposium on MND/ALS. 129:54-55. (May 1995).
  • ABRAHAMS S; LEIGH PN; KEW JJM; GOLDSTEIN LH; LLOYD CML; BROOKS DJ. A positron emission tomography study of frontal lobe function (verbal fluency) in amyotrophic lateral sclerosis. 5th International Symposium on MND/ALS. 129:44-46. (May 1995).
  • Brooks DJ. PET studies in neuropharmacology. Novel approaches. NATO Advanced Research Workshop on Positron Emission Tomography - A Critical Assessment of Recent Trends. 51:239-248. (1998).
  • Rascol O; Brooks DJ; Korczyn AD; De Deyn PP; Clarke CE; Lang AE; 056 Study Grp. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. XIIIth International Congress on Parkinsons Disease. 342:1484-1491. (18 May 2000).
  • Brooks DJ. Movement disorders: An overview. 1st Solvay Pharmaceuticals Conference. 1:5-13. (2002).
  • Turner MR; Rabiner EA; Doder M; Shaw CE; Grasby PM; Brooks DJ; Leigh PN. [C-11]-WAY100635 PET: A surrogate marker for MND?. Joint Meeting of the Association-of-British-Neurologists/British-Neuropsychiatry-Association. 74:407-407. (Mar 2003).
  • Hammers A; Asselin MC; Hinz R; Brooks DJ; Duncan JS; Koepp MJ. An [C-11] diprenorphine PET study of endogenous opioid release following spontaneous seizure. Spring Meeting of the Association-of-British-Neurologists. 75:1222-1222. (Aug 2004).
  • Hammers A; Asselin MC; Brooks DJ; Luthra SK; Hume SP; Thompson PJ; Turton DR; Duncan JS; et alKoepp MJ. Correlation of memory function with binding of [C-11]CNS 5161, a novel putative NMDA ion channel PET ligand. 5th International Symposium on Functional Neuroreceptor Mapping of the Living Brain. 22:T54-T55. (Feb 2004).
  • Linford-Hughes AR; Davies SJC; Taylor LG; Williams TM; Daglish MRC; Pandit S; Hammers A; Brooks DJ; et alNutt DJ. A PET study of opioid receptors in abstinent alcohol dependent patients. Summer Meeting of the British-Association-for-Psychopharmacology. 18:A41-A41. (Sep 2004).
  • Hammers A; Asselin MC; McCulloch G; Hinz R; Bench CJ; Brooks DJ; Grasby PM; Duncan JS; et alKoepp MJ. The role of the thalamus in spontaneous partial seizures and seizures induced by ECT: An [C-11] diprenorphine pet study. Annual Meeting of the American-Epilepsy-Society. 45:111-112. (Jul 2004).
  • Pavese N; Gerhard A; Tai YF; Ho AK; Turkheimer F; Barker RA; Brooks DJ; Piccini P. In vivo imaging of activated microglia by 11C-(R)-PK11195 PET. A biomarker of neuroinflammation in Huntington's disease?. World Congress on Huntingtons Disease. 76:U26-U27. (Oct 2005).
  • Tai YF; Pavese N; Gerhard A; Tabrizi SJ; Barker RA; Brooks DJ; Piccini P. Microglial activation in presymptomatic Huntington's disease gene carriers: A C-11-PK11195 pet study. World Congress on Huntingtons Disease. 76:U5-U5. (Oct 2005).
  • Khan NL; Bhatt M; Brooks DJ; Korlipara P; Schapira A; Piccini P; Wood NW; Bhatia K. An Indian kindred with reversible dystonia and parkinsonism. Fall Meeting of the Association-of-British-Neurologists. 78:210-210. (Feb 2007).
  • Williams TM; Lingford-Hughes A; Daglish MRC; Taylor LG; Hammers A; Brooks DJ; Grasby P; Nutt DJ. Increased opiold receptor binding in early abstinence from dependent opioid and alcohol use and relationship to craving. 17:S78-S79. (Mar 2007).
  • Turkheimer FE; Edison P; Pavese N; Roncaroli F; Hammers A; Gerhard A; Hinz R; Tai YF; et alBrooks DJ. Supervised reference region extraction for the quantification of [11C]-(R)-PK11195 brain studies. 31:T18-T18. (2006). DOI.
  • Brooks DJ. Movement disorders. 253:4-4. (May 2006).
  • Edison P; Archer H; Hinz R; Fox N; Brooks DJ. Relationship between the distribution of microglial activation, amyloid plaque load and cerebral glucose metabolism in Alzheimer's disease (AD): An 11C-PK11195, 18F-FDG and 11C-PIB PET study. 54:S6-S7. (Apr 2006).
  • Gerhard A; Brooks DJ. The role of positron emission tomography (PET) in the assessment of PSP. 21:435-437. (Mar 2006).
  • Turner MR; Cagnin A; Turkheimer FE; Miller CCJ; Shaw CE; Brooks DJ; Banati RB; Leigh N. In vivo study of cerebral microglial activation in MND using [C-11]-PK11195 PET. 75:1214-1214. (Aug 2004).
  • Bailey DL; Whone AL; Pavese N; Brooks DJ. Standardised methodlogy with centralised analysis for a PET multi-centre clinical trial using change in [F-18]-DOPA influx rate constant as the primary endpoint. 44:118P-118P. (May 2003).
  • Williams TM; Daglish MRC; Lingford-Hughes A; Hammers A; Brooks DJ; Myles JS; Nutt DJ. Regional cerebral increases in opioid receptor density in early abstinence from methadone: a PET study in man. 13:S31-S31. (Mar 2003).
  • Gill SS; Patel NK; Hotton GR; O'Sullivan K; Brooks DJ; Svendsen CN; Heywood P. Chronic intraputaminal infusion of glial derived neurotrophic factor (GDNF) in the treatment of advanced Parkinson's disease. 12:313-313. (2003).
  • Hammers A; Asselin MC; Hinz R; Brooks DJ; Duncan JS; Koepp MJ. Enclogenous opioid release following spontaneous seizures: An [11]C-diprenorphine PET. 44:182-183. (2003).
  • Williams TM; Daglish MRC; Lingford-Hughes A; Hammers A; Brooks DJ; Myles JS; Nutt DJ. Altered brain opioid receptor density after withdrawal from methadone treatment. 16:A54-A54. (Sep 2002).
  • Brooks DJ. Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease. 247:11-18. (Apr 2000).
  • ABRAHAMS S; LEIGH PN; KEW JJM; GOLDSTEIN LH; LLOYD CML; BROOKS DJ. A POSITRON EMISSION TOMOGRAPHY STUDY OF FRONTAL-LOBE FUNCTION (VERBAL FLUENCY) IN AMYOTROPHIC-LATERAL-SCLEROSIS. 129:44-46. (May 1995).
  • ABRAHAMS S; GOLDSTEIN LH; LLOYD CM; BROOKS DJ; LEIGH PN. COGNITIVE DEFICITS IN NONDEMENTED AMYOTROPHIC-LATERAL-SCLEROSIS PATIENTS - A NEUROPSYCHOLOGICAL INVESTIGATION. 129:54-55. (May 1995).
  • KEW JJM; BROOKS DJ; RASSINGHAM RE; ROTHWELL JC; FRACKOWIAK RSJ; LEIGH PN. CORTICAL FUNCTION IN PROGRESSIVE MUSCULAR-ATROPHY AND AMYOTROPHIC-LATERAL-SCLEROSIS. 124:72-72. (Jul 1994).
  • BROOKS DJ. DETECTION OF PRECLINICAL PARKINSONS-DISEASE WITH PET. 41:24-28. (May 1991).
Share this on DeliciousTweet thisDigg thisStumble thisShare this on Facebook